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ABSTRACT 
Mycobacterium tuberculosis (Mtb) infection, remains one of the major worldwide threats, affecting 
about one third of the human population. The vaccine Bacillus Calmette-Guérin (BCG), although 
effective against childhood disseminated tuberculosis (TB), has variable and limited efficacy against 
adulthood pulmonary TB. Co-infection with the human immunodeficiency virus (HIV) and the 
emergence of multidrug resistant strains of Mtb has further complicated the TB control and 
eradication. It is becoming increasingly recognized that the Mtb complex (MTBC) is more 
genetically diverse than previously believed. In our laboratory, we have been interested in the study 
of the differential host-pathogen interactions among Mtb strains, particularly those from the Beijing 
family. Among this Mtb lineage, we found that strain 02-171, is recognized by both toll-like receptor 
2 (TLR2) and TLR4, resulting in a distinct outcome of infection in vitro and in vivo.  
In the first part of this work we investigated the impact of TLR4 triggering on T cell responses during 
a primary infection by 02-171 Mtb strain via the aerosol route. We found that TLR4 triggering 
increased the frequency of lung CD4+ T cells, which appears to be associated with enhanced T 
cell recruitment. Furthermore, TLR4 activation did not impact interferon (IFN)- response neither 
nitric oxide synthase 2 (Nos2) expression. In accordance, TLR4 triggering did not impact bacterial 
growth after aerosol 02-171 infection. Interestingly, TLR4 absence increased lung interleukin (IL)-
17 CD4+ T cell responses. Overall, our data suggest no apparent function for TLR4 triggering 
during a primary infection with a low dose of 02-171 Mtb strain inoculated via the aerosol route. 
In the second part of this work, we focused on the role of TLR4 activation by 02-171 Mtb strain 
during a recall response after BCG vaccination. We found that BCG vaccination is effective at 
controlling the progression of infection and lung pathology in 02-171 infection. This finding does 
not support the idea that Beijing strains are resistant to protection evoked by BCG vaccination. In 
vaccinated mice, we observed an overall anticipation of protective responses, particularly the 
presence of multifunctional and granulocyte macrophage colony-stimulating factor (GM-CSF)-
producing CD4+ T cells. Furthermore, while wild-type (WT) vaccinated mice upregulated IL-17 
responses, in TLR4 deficient mice such induction was not observed, without impairment in BCG-
induced protection. Overall, TLR4 triggering seems to be not essential for BCG-mediated immunity 
against 02-171 infection. Understanding, the mechanisms that dictate the development of adaptive 
immunity will certainly contribute for the identification of T cell subsets and other immune factors 
important for protection against Mtb infection, as well as, novel correlates of protection, particularly 
relevant to evaluate the effectiveness of new TB vaccine candidates.  
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RESUMO 
A infeção por Mycobacterium tuberculosis (Mtb) constitui um grave problema em todo o mundo, 
afetando cerca de um terço da população humana. A vacinação com o Bacilo Calmette-Guérin 
(BCG), embora eficaz contra tuberculose (TB) disseminada na infância, tem uma eficácia variável 
e limitada contra a TB pulmonar em idade adulta. A co-infeção com o vírus da imunodeficiência 
humana (HIV) e o aparecimento de estirpes multirresistentes de Mtb contribuiu para o deficiente 
controlo e erradicação da TB no mundo.  
Mtb é geneticamente mais heterogéneo do que inicialmente se acreditava. O nosso laboratório 
interessa-se pelo estudo da heterogeneidade das interações patogénio-hospedeiro com estirpes de 
Mtb, nomeadamente as da família Beijing. Recentemente, publicámos que a estirpe 02-171 desta 
linhagem ativa o recetor do tipo Toll 2 (TLR2), como também o TLR4, com consequências na 
resposta do hospedeiro in vitro e in vivo.  
Na primeira parte do trabalho nós investigamos o papel da ativação do TLR4 no desenvolvimento 
de respostas T durante uma infeção primária pela estirpe 02-171. Nós observamos que a ativação 
do TLR4 induz um aumento na frequência de células T CD4+ do pulmão, o que parece estar 
associado com um aumento do recrutamento dessas mesmas células. Apesar da ativação do TLR4 
não ter afetado a resposta do interferão (IFN)- nem a expressão da óxido nítrico sintase 2 (Nos2), 
a ausência deste recetor causou o aumento da resposta IL-17 pelas células T CD4+ no pulmão. 
Em suma, os dados obtidos neste trabalho sugerem que a ativação do TLR4 durante uma infeção 
primária por 02-171 não confere proteção contra a infeção.  
Na segunda parte do trabalho focámo-nos no papel da ativação do TLR4 pela estirpe 02-171 
durante a resposta de memória após a vacinação com BCG. Observamos que a vacinação é eficaz 
no controlo da progressão da infeção e inflamação pulmonar induzida pela estirpe 02-171, não 
suportando a ideia de que estirpes Beijing são resistentes à proteção conferida pela vacinação 
com BCG. Em ratinhos vacinados, observamos uma antecipação global da resposta protetora, em 
particular a presença de células T CD4+ multifuncionais e produtoras de GM-CSF. Além disso, nos 
ratinhos wild-type (WT) vacinados observamos um aumento da resposta IL-17, enquanto em 
ratinhos vacinados deficientes para TLR4 o aumento desta resposta induzida pela vacinação não 
foi observada, sem qualquer prejuízo para a proteção induzida pela imunização por BCG. Em 
suma, a ativação do TLR4 não parece ser essencial para a imunidade mediada por BCG após a 
infeção com 02-171. Perceber os mecanismos que determinam o desenvolvimento da imunidade 
adaptativa contribuirá para a identificação de subpopulações de células T e outros fatores 
imunológicos importantes para a proteção contra TB, bem como, para a identificação de novos 
biomarcadores de proteção, particularmente relevantes para a avaliação da eficácia de novas 
vacinas. 
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1.1 Tuberculosis: a problem with major proportions 
Tuberculosis (TB) is an infectious respiratory disease that essentially occurs in the lung, although 
it can also affect other organs (as lymph nodes (LN), meninges and bone) – extrapulmonary TB 
[1, 2]. Despite the increasing understanding of the disease pathogenesis, TB still has a significant 
impact on public health worldwide (Figure 1), being the second leading cause of death from an 
infectious disease, second only to the human immunodeficiency virus (HIV) [1]. In 2013, the World 
Health Organization (WHO) Global Tuberculosis Report estimates that there were approximately 
8.6 million new TB cases and around 1.3 million TB deaths (1.0 million among HIV-negative people 
and 0.3 million HIV-associated TB deaths) [1]. The number of deaths resulting from TB is still 
incongruously high, given that most of the cases are avoidable if patients had access to primary 
health care for diagnosis and if the right treatment was provided and accomplished [1]. Nowadays, 
despite the descending trends in the incidence rates of the disease, the situation in Portugal is 
considered one of the most severe among Western European countries (Figure 1) [3]. 
TB is a highly transmittable disease, due to the fact that it is disseminated through the air [1]. 
When a patient with active disease sneezes, coughs or spits, the bacilli that cause the disease 
spread into the air and can then be inhaled by surrounding people [1]. It is estimated that one-
third of the world’s population is infected with Mycobacterium tuberculosis (Mtb), the causative 
agent of most cases of TB [1, 2, 4], with only 5 to 10% of those people developing active disease 
with symptoms (fever, fatigue, cough with bloody sputum, night sweats and weight loss) and 
culturable bacilli in sputum [2, 5, 6]. In the remaining TB cases, the infected individuals develop 
an effective immune response that culminates in latent infection without clinical symptoms [7]. In 
those cases mycobacteria rests in the host inside the granuloma – a hallmark of TB disease [8, 
9]. However, those individuals are susceptible to disease reactivation, which normally happens in 
situations associated with immunosuppression [7]. Just a small percentage of individuals remain 
uninfected upon exposure to Mtb possibly owing to the expression of high innate immunity [8, 10].  
In the past years, TB renewed a new significance mainly due to diabetes, co-infection with HIV and 
the emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains of Mtb 
[2, 6, 7, 11]. 
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Figure 1 – Estimated worldwide TB incidence rates in 2012, as determined by the WHO. From [1]. 
 
1.2 Mycobacterium tuberculosis 
TB is caused by a group of phylogenetically related species collectively denominated as Mtb 
complex (MTBC) [9, 12]. Besides Mtb, other Mycobacterium species can cause disease like 
Mycobacterium africanum, Mycobacterium canettii, Mycobacterium microti, Mycobacterium bovis 
and Mycobacterium avium in immunocompromised individuals [9]. Mtb is considered a Gram-
positive and an acid-fast bacteria, characterized by slow growth, dormancy and genetic variability 
among Mtb strains [5, 12]. Mtb is a facultative intracellular bacteria that grows inside phagocytic 
cells, particularly macrophages and monocytes. One of the most strictly characteristics of this 
pathogen is the complex cell wall, rich in lipids. The cell wall core comprises peptidoglycan bound 
to arabinogalactan, which in turn is attached to mycolic acids. The most external layer, also 
denominated capsule, consists in mannose-capped lipoarabinomannan (Man-LAM), lipomannan 
(LM), and manno-glycoproteins [13, 14].  
Genomic studies revealed that Mtb consists in 7 main lineages and 15 sublineages based on the 
analysis of large sequence polymorphisms (LSPs) and other phylogenetic markers [12, 15, 16]. 
Each lineage is linked to specific geographical regions. For instance, in Europe, the Euro-American 
lineage of Mtb prevails, which suggest that lineages of Mtb are more adapted to particular human 
populations [15]. 
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The Beijing genotype (East-Asia lineage) has been described as one of the most successful lineages 
of Mtb [17, 18]. Strains are classified as belonging to the Beijing family based on their distinct 
spoligotype and IS6100 restriction fragment length polymorphism (RFLP) patterns [17, 18]. Strains 
of this clade were firstly found in China and Mongolia, but their frequency has emerged worldwide, 
representing nowadays about 13% of the isolates [17, 18]. Strains of the Beijing genotype are a 
major concern, because of their global association with worldwide TB epidemics, high virulence 
and mortality, increased drug resistance, non-protective immune responses and possible inefficacy 
of Bacillus Calmette–Guérin (BCG) vaccination [17-21].  
 
1.3 Mycobacterium tuberculosis recognition by Toll-like receptors 
The innate immune response is initiated by the activation of germline-encoded receptors, globally 
designated as pattern recognition receptors (PRRs), which recognize highly conserved microbial 
features, in a wide range of pathogens [22, 23]. These microbial structures, known as pathogen-
associated molecular patterns (PAMPs), are essential biomolecules of the microorganisms, that 
therefore do not suffer changes easily [22]. During infection, several host cell receptors are involved 
in the pathogen recognition [22]. For example, in the case of Mtb, the mannose receptor, 
complement receptors, dectin-1, dendritic cell-specific intercellular adhesion molecule-3-grabbing 
nonintegrin (DC-SIGN), mincle, nucleotide-binding oligomerization domain (NOD-) like receptor 
(NLR), retinoic acid-induced gene (RIG)-I-like receptor (RLR), Fc receptors, scavenger receptors and 
toll-like receptors (TLRs) are involved in pathogen recognition by innate immune cells [8, 13, 24, 
25]. From here on, we focus on TLRs, the scope of this thesis.  
TLRs are expressed on several immune cells, including macrophages, dendritic cells (DCs), some 
T cell subsets, B cells and also non-immune cells such as epithelial cells and fibroblasts [26] [22]. 
To date, 12 TLRs have been characterized in mice, while the human TLR family comprises 10 
known members [23, 24]. TLRs differ from each other essentially in ligand specificity, expression 
patterns and signaling pathways triggered downstream TLR activation [22]. Moreover, TLRs can be 
expressed either extra- or intracellularly. In that sense, TLR1, -2, -4, -5 and -6 are expressed on the 
cell surface and therefore recognize mainly pathogen membrane structures [23, 24]. In contrast, 
TLR3, -7, -8 and -9 are localized in intracellular organelles and recognize mostly nucleic acids [23, 
24]. The TLR triggering by PAMPs activates intracellular signaling cascades that induce the 
expression of genes involved in antimicrobicidal mechanisms [23, 24]. Upon ligand binding the 
interaction among TLRs and adaptor proteins is initiated. Myeloid differentiation factor 88 (MyD88) 
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adaptor molecule is critical for all TLR signaling with exception of TLR3 (Figure 2). TLR3 signals 
exclusively via toll-interleukin 1 receptor (TIR) domain-containing adaptor protein inducing 
interferon (IFN)-Ⱦ (TRIF) adaptor molecule, while TLR4 utilizes both MyD88 and TRIF (Figure 2). In 
the plasma membrane, TLR4 interacts with TIR domain-containing adaptor protein (TIRAP) and 
MyD88 triggering signaling cascades that culminates in the activation of nuclear factor kappa-B 
(NF-κB) or in the phosphorylation of mitogen-activated protein kinase (MAPK), leading to the 
production of proinflammatory cytokines and chemokines that intervene in the immune response 
(Figure 2). After internalization, TLR4 form a complex with TRIF-related adaptor molecule (TRAM) 
and TRIF (Figure 2). In addition to NF-κB and MAPK activation, the TRIF-dependent pathway leads 
to the activation of IFN regulatory factors (IRFs) with consequent transcription of type I IFN (Figure 
2) [23, 24]. 
 
Figure 2 – TLR signaling pathway. From [23]. 
 
TLR2 in association either with TLR1 or TLR6, TLR4 and TLR9 have been described as mediating 
in vitro and in vivo recognition of Mtb [8, 27-34]. TLR2 is involved in the recognition of 38-kDa 
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protein, 19-kD glycoprotein, LAM, LM, arabinofuranosyl LAM (AraLAM), phosphatidyl-myo-inositol 
mannoside (PIM), triacylated (TRL2/TLR1) and dyacylated (TLR2/TLR6) lipoproteins of Mtb. TLR4 
also recognizes PIM and heat-shock protein 60/65, while TLR9 is activated by unmethylated 
cytosine-phosphate-guanine (CpG) motifs in mycobacterial DNA [8, 13, 30].  
As anteriorly referred, TLR2 is known to recognize several mycobacteria ligands, being accepted 
as the main TLR for the in vitro activation upon Mtb infection [8]. In vitro studies of TLR activation 
showed that TLR2 triggering by Mtb ligands causes the inhibition of macrophage antigen 
presentation via major histocompatibility complex (MHC) class II and also blocks the response of 
macrophages to IFN-, which suggest that TLR2 signaling could negatively impact macrophage 
functions [8]. Additionally, TLR2 and TLR9 are important receptors for driving interleukin (IL)-12 
production in response to Mtb [30].  
Data from our laboratory showed that in a panel of Mtb strains, including the reference Mtb strain 
H37Rv, and strains from the Beijing lineage, most of the Mtb strains were recognized by TLR2 by 
bone marrow-derived macrophages (BMDM) [34]. However, we also found that Mtb Beijing strain 
02-171 was also recognized by TLR4 [34]. This Mtb strain induced a different profile of cytokines 
in BMDM, with high pro- and anti-inflammatory responses [34]. Interestingly, only 02-171-infected 
BMDM produced IFN-Ⱦ, a type I IFN [34]. 
In vivo studies showing a fatal infection of mice deficient for MyD88, evidence the role for TLR 
activation in the control of Mtb infection [35, 36]. Nevertheless, the involvement of individual TLR 
signaling for the protection against Mtb infection remains to be elucidated. In vivo experimental 
Mtb infection using mice deficient for specific TLRs suggests a differential role of TLRs in Mtb 
infection. Mice deficient for TLR9 display an increased susceptibility to high dose of Mtb infection 
than wild-type (WT) animals [30]. Also upon a high dose of Mtb infection TLR2 defective mice 
showed a reduced bacterial clearance compared to WT mice [28, 33]. However, in response to a 
low dose of Mtb infection, TLR2 and -9 deficient mice presented similar protection compared to 
WT mice [30, 33]. Furthermore, TLR2 triggering has a key role on the regulation of p19 (Il-23a) 
expression in response to Mtb and therefore impact the maintenance of T helper 17 (Th17) cells 
in the lung of Mtb-infected animals [27]. 
Regarding the role of TLR4 triggering during Mtb there are inconsistent results. Some studies 
showed that TLR4-defective C3H/HeJ mice were as resistant to aerosol Mtb infection as C3HHeN 
control mice [32, 33]. In contrast, other reports showed that TLR4 mutant mice were more 
susceptible to Mtb infection when compared to WT mice [29, 31]. Recently, our group showed that 
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TLR4 deficient mice were more susceptible to an intranasal infection by a TLR4-activating Mtb 
strain, while upon infection by a TLR2-activating Mtb strain TLR4 deficient mice were as resistant 
as WT mice, supporting the involvement of TLR4 during a protective response to at least some 
strains of Mtb [34].  
Human genetic variations have been reported within the TLR genes, which might affect their 
functionality and increase TB susceptibility. Indeed, some human TLR4 polymorphisms, mainly 
TLR4 Asp299Gly and Thr399Ile polymorphisms, have been associated with TB susceptibility in 
Asian Indian and in a cohort of HIV-infected Tanzanian patients [37, 38]. However, in Southeastern 
Iran, Gambia, South Indian and Southeastern Chinese population the same association was not 
found [39-43]. Different polymorphisms in TLR2 in cohorts from Turkey, Vietnam, Pakistan, 
Southeast Iran and Korea associated with increased susceptibility to TB [44-47], whereas such 
association was not observed in cohorts from Southeastern China and South India [41, 43, 48]. 
Finally, TLR9 polymorphisms have also been shown to associate with TB in cohorts from Mexican, 
China, Indonesia and Vietnam [49-51]. However, the same association was not found in 
Southeastern Iran and India [39, 41]. These discrepant data might be explained on the basis of a 
dynamic host-pathogen genetic and pathogen phenotypic interplay. Indeed, further studies are 
needed to clarify the specific contribution of TLRs for the outcome of Mtb infection.  
TLR triggering can also play a role during adaptive immunity [52, 53]. In the absence of T cell 
receptor (TCR) signaling, murine Th1 effector T cells can be activated by TLR2 ligands with 
consequent IFN- production. In those conditions, TLR2 agonists can also stimulate proliferation 
and survival of Th1 cells [53, 54]. Moreover, TLRs induce T cell differentiation through the activation 
antigen presenting cells (APCs) that in response to TLR binding produce polarizing cytokines, as 
IL-12 and IL-23, and chemokines, necessary for cell recruitment to the site of infection [53]. Thus, 
T cell activation can be induced either through T cell/APC interactions or directly via TLR activation 
in the absence of APCs. TLR2 deficiency by compromising p19 (IL-23a) expression limits Th17 cell 
responses to Mtb infection [27]. Memory T cells are also responsive to TLR ligands. In this case, 
TLR triggering could help in T cell survival and in the mounting of a fast memory response [53]. 
Furthermore, TLR agonists can temporally suppress regulatory T cell (Treg) function, allowing the 
activation of pathogen-specific T cells [53].  
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1.4 Innate immune response to Mycobacterium tuberculosis  
Upon aerosol exposure, Mtb spreads into the lungs, firstly infecting the alveolar resident 
macrophages [5, 6]. After that, other cells take part in this process. APCs, such DCs and 
macrophages, are the main innate immune cells involved in protection against TB [6, 55]. Following 
Mtb recognition, TLR triggering in APCs promotes the phagocytic process and activates their 
microbicidal mechanisms in order to eliminate or reduce Mtb growth [8]. Upon phagocytosis and 
inside the phagolysosome (formed by phagosome fusion with lysosomes), Mtb is eradicated 
through several mechanisms, such as decrease of the phagosomal pH, production of reactive 
oxygen intermediates (ROIs) such as hydrogen peroxide (H2O2) and reactive nitrogen intermediates 
(RNIs) like nitric oxide (NO), and release of hydrolytic enzymes or other antimicrobicidal 
components into the phagosome [56]. However, Mtb can resist to macrophage microbicidal 
mechanisms and survive due to modulation of the host immune response, for instance preventing 
the phagolysosome fusion [6, 57]. Upon activation by TLRs, and in the presence of IFN- and tumor 
necrosis factor (TNF), activated macrophages produce NO via inducible nitric oxide synthase (iNOS) 
enzyme using L-arginine and molecular oxygen as substrates [5, 56, 58]. In murine models of 
infection, Nos2 (the gene encoding for iNOS) deficient (NOS2-/-) mice have an impaired clearance 
of Mtb infection compared to WT-infected mice, corroborating the protective role of NO against Mtb 
infection in mice [5, 56, 58]. However, whether NO production is relevant to human macrophage 
microbicidal mechanisms remains unclear [6]. 
Despite the important function of macrophages in eliminating Mtb infection, these cells are poor 
activators of naïve T cells [59]. In contrast, DCs are the main APCs able to sense, uptake, process 
and present mycobacterial antigens [8]. Upon recognition, immature DCs phagocyte Mtb or Mtb-
infected apoptotic cells at the site of infection. Upon maturation, DCs migrate to draining LN to 
present mycobacterium antigens coupled with MHC molecules to naïve T lymphocytes initiating an 
antigen-specific adaptive immune response [4, 55]. During this maturation process, costimulatory 
molecules as cluster of differentiation (CD)40, CD80, CD86 and MHC-II molecules are upregulated 
and polarizing cytokines, as IL-12, IL-23, IL-1β, TNF and IL-6 involved in T cell differentiation, and 
chemokines are secreted (Figure 3) [4, 22, 55, 60, 61]. All these processes are controlled by PPR 
activation on DCs.  
Despite the central role of DCs and macrophages in innate immunity against Mtb, other innate 
immune cells as neutrophils, natural killer (NK) cells and δ T cells are also involved in Mtb 
challenge [5, 56]. For instance, after Mtb infection neutrophils are rapidly recruited to the site of 
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infection, where they phagocytize bacteria [62]. However, the role of neutrophils is still unclear. 
Despite conflicting, studies where neutrophils were depleted and mice infected with Mtb suggest 
that these cells might contribute to early defense against Mtb infection. Nevertheless, in the chronic 
phase of the disease neutrophil accumulation is most likely to contribute to pathology [62].  
NK cells are granular lymphocytes with both cytotoxicity and cytokine-producing effector functions 
[63]. NK cells are able to lysis Mtb-infected cells, such monocytes, through the cytotoxicity 
receptors as NK cell p46-related protein (NKp46) and NK group 2, member D (NKG2D) [64, 65]. 
In addition, NK cells also produce IFN-, which contributes for the initiation of macrophage 
microbicidal mechanisms, resulting in early resistance to many infections, such as Listeria 
monocytogenes [66]. In a mouse model with intact T cell function, antibody depletion of NK cells 
during in vivo Mtb infection, does not cause an impairment in Mtb control [67]. In contrast, studies 
in severe combined immunodeficiency (SCID) mice have suggested a putative protective role for 
NK cells in the immune response to Mtb [66]. Indeed, IFN- secreted by NK cells does not seem 
to be essential for normal control of Mtb infection, but this response may become important in 
situations in which T cell function is compromised, such as in HIV patients or SCID mice [66].  T cells, are a subtype of T cells that classically belongs to the innate arm of the immune system 
[68].  T cells, differ from classical ȽȾ T cells, in the range of antigens that they can recognize, 
as non-peptide antigens, independently of MHC-II [68].  T lymphocytes are able to efficiently kill 
extracellular and intracellular Mtb by releasing the cytotoxic molecule granulysin [68].  T cells 
are also able to secrete IFN- [68]. In addition to IFN-, it has been reported that δ T cells are the 
main source of IL-17 production in response to Mtb infection [69]. In the mouse model, the 
absence of δ T cells results in defective granuloma formation, however, the bacterial burden in 
the lungs was similar to the exhibited by WT mice [70]. The precise role of these cells in Mtb 
infection remains unclear [68]. 
 
1.5 Adaptive immune response to Mycobacterium tuberculosis 
 
1.5.1 General 
In contrast to innate immunity, adaptive immunity relies on highly specialized cells that react 
specifically to pathogen antigens and have the ability to generate immunologic memory that leads 
to an enhanced and fast response to following encounters. B (humoral immunity) and T (cell 
mediated immunity) cells are the main effector cells of the adaptive immune arm [71].  
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The role of B cells during Mtb infection is still unclear. Murine models of B cell deficiency showed 
that after high, but not low inoculum dose of Mtb, mice were more susceptible to infection 
compared to control mice [4, 72, 73]. 
T cells play a fundamental protective role in immunity to TB [2, 4, 5, 56]. CD8+ T cells or cytotoxic 
T cells recognize the cognate antigen in the context of MHC-I molecules and besides cytokine 
production, such as IFN-, that activates macrophage activity, CD8+ T cells can directly eliminate 
Mtb-infected cells by the release of perforin, granzymes, and granulysin [56, 74]. Studies with Ⱦ2-
microglobulin (a component essential for MHC-I expression), transporter associated with antigen 
processing 1 (TAP-1) (involved in the transport of cytosolic peptides to the endoplasmic reticulum, 
where they bind to MHC-I molecules) and CD8Ƚ gene disrupted mice suggest a protective role of 
CD8+ T cells in Mtb infection [5, 56, 74].  
CD4+ T cells or Th cells recognize peptides presented by MHC-II molecules and act essentially by 
cytokine production [56]. Since the study of CD4+ T cell response is the scope of this thesis, we 
now focus mainly in CD4+ T cell responses. 
 
 1.5.2 CD4+ T cell responses during Mycobacterium tuberculosis infection 
T cells mainly CD4+ T cells have extreme importance in resolution of Mtb infection in human and 
in mice [4, 5, 56]. This fact was confirmed by the observation that individuals infected with HIV, 
who present low numbers of CD4+ T cells, are very susceptible to Mtb [2, 4, 75]. Also murine 
studies have shown, by antibody depletion of CD4+ T cells or by the use of genetically manipulated 
mice, that the CD4+ T cells are required for Mtb control [4, 5, 56, 76]. 
Upon Mtb infection, DCs phagocyte Mtb at the site of infection. Mature DCs migrate to the LN to 
present processed mycobacterium antigens to naïve T lymphocytes [4]. After TCR engagement and 
depending of cytokine milieu and co-stimulation provided by APCs, naïve CD4+ T cells are 
activated, proliferate and become committed to one of several lineages of Th cells, including Th1, 
Th17 and Treg cells among others (Figure 3) [4, 77, 78]. Effector Th cells migrate to the lungs in 
response to specific inflammatory mediators and develop an immune response that further 
promotes activation of macrophage microbicidal mechanisms [4].  
Following Mtb challenge, the induction of T cell polarizing cytokines is dependent of PRRs that are 
expressed and activated in APCs [4]. In the absence of IFN- and after Mtb-induced TLR2-
dependent DCs stimulation, IL-23 is higher expressed than IL-12 [79], whereas in the presence of 
IFN- Mtb-infected DCs secrete both IL-12 and IL-23 which potentiate both Th1 and Th17 
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polarization [79, 80]. In vitro and after Mtb infection both TLR2 and TLR9 activation induce the 
production of IL-12p40 by DCs [30, 80]. IL-12p40 subunit is shared by IL-12 and IL-23, key innate 
cytokines involved in Th1 and Th17 responses. Consequently the innate stimulus that leads to the 
production of these cytokines has an important impact in the type of Th response and has to be 
different and highly regulated [80]. Recently, we reported that certain Beijing strains of Mtb 
preferentially activate TLR2, whereas others also activate TLR4 resulting in a distinct cytokine 
pattern in vitro and in vivo [34]. Thus, it is possible that distinct Mtb strains by differentially 
stimulating DCs, lead to secretion of distinct polarizing cytokines which may impact the Th cell 
response generated. Indeed, the work developed in this thesis focus on the impact of TLR4 
triggering by a TLR4-activating Mtb strain on the development of adaptive immunity.   
Each T cell lineage is characterized by their cytokine production profile, function and different 
patterns of cell surface molecules (Figure 3) [33, 77, 78]. The signaling pathways triggered in 
CD4+ T cells by polarizing cytokines leads to the activation of signaling transducer and activator of 
transcription (STAT) proteins which are involved in induction and binding of the main transcription 
factors to genes that are under their influence [77, 81]. The hallmark cytokine of Th1 cells is IFN-, but these cells also produce IL-2, TNF and lymphotoxin (Figure 3) [77, 78, 82]. The main cytokine 
involved in Th1 polarization is IL-12 (Figure 3) [77, 78, 81]. IL-12 is a heterodimer formed by two 
subunits namely IL-12p35 and IL-12p40 that signal through the IL-12 receptor (IL-12R) composed 
by IL12RȾ1 and IL12RȾ2 chains [83]. Mtb infected-DCs secrete IL-12 that potentiates IFN- 
production by those cells [84]. T box expressed in T cells (T-bet) is the master transcription factor 
associated with IFN- production and Th1 differentiation (Figure 3) [77, 78, 81]. After TCR 
engagement, the binding of IFN- to IFN-R triggers the activation of STAT1 and T-bet [77, 78]. 
Following, T-bet further induces the production of IFN- and IL-12R, which potentiates the action 
of IL-12 and subsequently the Th1 expansion and maintenance (Figure 3) [77, 78, 85]. STAT4 is 
another protein that is involved in Th1 differentiation and intervenes in IL-12 signaling pathway 
(Figure 3) [77, 78, 85].  
In Mtb infection, Th1 cells are fundamental for protective immunity [2, 4, 5, 56]. The main 
functions of IFN- secretion in Mtb infection are to enhance macrophage phagocytosis and increase 
the induction of NO and ROIs, which are mechanisms involved in pathogen clearance [5, 56]. 
Humans with defects in the production or signaling of IL-12 and IFN- cytokines are highly 
susceptible to TB [4, 86]. Furthermore, the importance of IL-12 and IFN- was demonstrated in 
mice deficient in those molecules that succumbed early in response to Mtb infection [56]. Studies 
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revealed that IL-12p40 deficient mice are more susceptible to Mtb infection than IL-12p35 
knockout mice, suggesting a protective role for IL-12p40 [2]. Indeed, upon Mtb infection IL-12p40 
homodimers are involved in DC migration and T cell activation [2, 84]. Additionally, the arrival and 
accumulation of IFN--producing T cells in the lungs is temporally associated with the stop of 
bacterial growth [4, 87, 88]. However, a recent report using a model of adoptive transfer of Mtb 
specific effector CD4+ T cells, propose a mycobactericidal effector function of CD4+ T cells that is 
independent of both IFN- and TNF production [89]. These findings show that, despite the fact that 
CD4+T cells and IFN- are important for Mtb control, CD4+ T cells can mediate protection by other 
IFN--independent mechanisms during primary and secondary challenge [89, 90].  
Upon Mtb infection, and in addition to Th1 cells, Th17 cells are also induced [80]. Th17 cells 
secrete IL-17A (IL-17), IL-17F and IL-22 as their signature cytokines (Figure 3) [80, 91]. The 
cytokines that drive Th17 differentiation are IL-6, IL-21 and transforming growth factor (TGF)-Ⱦ in 
low quantities (Figure 3) [80, 91]. Others cytokines such IL-1Ⱦ and TNF act as cofactors during 
Th17 development [80, 91]. The main transcription factor involved in Th17 polarization is retinoic 
acid receptor related orphan receptor-t (ROR-t) [80, 91]. IL-6, IL-23 and TFG-Ⱦ intervene through 
activation of STAT3 pathway, which in turn induces ROR-t and IL-23R expression that allows Th17 
differentiation and maintenance (Figure 3) [80, 91, 92]. IL-23 is a heterodimeric cytokine formed 
by IL-12p40 and IL-23p19 subunits [91]. IL-23 plays an important function not in initial 
differentiation but in the later maintenance of Th17 phenotype, since that IL-23R is not expressed 
in naïve CD4+ T cells [77, 80, 91, 92]. During intracellular bacterial infections as Mtb infection the 
function of IL-17 is not well understood [71, 80, 93]. Recent reports propose that IL-17 confers 
protective immunity against some intracellular pathogens like Salmonella enterica and Listeria 
monocytogenes [76, 80].  In low dose of Mtb infection, the lack of IL-17 and IL-23 does not have 
a significant impact in the capacity of mice to limit Mtb infection. Although following a high dose 
challenge, IL-17 is required to the resolution of Mtb infection [80]. Th17 cells have an important 
role in induction of tissue inflammation and in development of immunopathology [80, 91, 93]. IL-
17 is a pro-inflammatory cytokine that induces the expression of several cytokines like IL-6, IL-8, 
IL-1Ⱦ, TNF, granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage–colony 
stimulating factor (GM-CSF); chemokines, as monocyte chemoattractant protein-1 (MCP-1), C-X-C 
motif chemokines 1 (CXCL1), CXCL9, CXCL10 and CXCL11 and antimicrobial proteins as 
defensins [80, 91]. Due to the induction of these chemokines by IL-17, this cytokine has an impact 
in neutrophil recruitment and inflammation. Indeed, after BCG infection and in absence of IL-17 
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the number of neutrophils recruited upon Mtb infection decreases as compared with WT mice [80]. 
Thus, upon Mtb infection, the IL-23/Th17 axis might be preponderant for granuloma organization, 
because it promotes chemokine secretion that potentiates an early neutrophil recruitment. 
Furthermore, the accumulation of neutrophils can potentiate IL-12 production and stimulate Th1 
differentiation [80]. However, if excessive IL-17 production occurs, continuous neutrophil 
recruitment leads to an exacerbate immune response and tissue damage [80, 94]. This 
exacerbated immune response can be inhibited by many regulators such as IFN-, IL-27 and IL-10 
whose signaling pathways inhibit Th17 differentiation preventing immunopathology [91, 92]. Thus, 
Th17 cells may have contrasting functions during Mtb infection either in fighting infection or in 
promoting tissue damage [80]. 
In sum, a fine balance between Th1 and Th17 responses is needed to stop bacterial growth and 
restrict immunopathology [80]. In this sense, Treg cells downregulate the immune response 
generated to avoid exacerbated pathology by secreting anti-inflammatory cytokines such as IL-10 
and TGF-Ⱦ (Figure 3). However, during Mtb infection Treg cells seem to play a detrimental role 
since they prevent pathogen clearance by suppressing protective CD4+ T cell responses [95]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Subsets of effector Th cells. Depending on the cytokine milieu present at the time of antigenic 
stimulation, naïve CD4+ T cells can differentiate into various subsets of Th cells (Th1, Th17, Treg and others). Specific 
transcription factors have been identified as master regulators of each subset. Differentiated Th cells are characterized 
by the secretion of a combination of effector cytokines. Adapted from [77, 78, 85, 91, 95].  
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One particular feature of TB is the slow induction of the adaptive immunity, which allows an 
uncontrolled growth of mycobacteria and the establishment of a chronic infection, which is 
detrimental for the outcome of infection [4]. The mechanisms responsible for the delayed T cell 
priming remain elusive, but some assumptions have been proposed [4]. It was demonstrated that 
dissemination of Mtb-infected DCs to LN is essential to priming T cell responses [4, 55, 96, 97]. 
One hypothesis is that Mtb suppresses APC function, thereby delaying the dissemination of 
antigens from the lungs to the LN. The slow bacterial growth of Mtb may also contribute for the 
delay in the initiation of adaptive immunity, since a long time is needed to reach an adequate 
antigen concentration to stimulate the immune system [4, 10, 98]. Effective levels of adaptive 
immune responses are only achieved after 18-20 days post-infection and consequently the 
bacterial growth and dissemination become controlled [4]. Between 2 to 6 weeks post-infection, 
the influx of lymphocytes and activated macrophages to the local of infection results in granuloma 
formation [4]. This structure consists in infected phagocytes delimited by activated giant cells and 
epitheloid macrophages and an external layer of lymphocytes and fibrosis. The granuloma main 
function is to encircle Mtb in immune cells and impede dissemination and transmission of infection 
into the rest of the uninfected lung [99, 100]. 
The dynamics and characteristics of the T cell response induced upon Mtb infection needs further 
investigation in order to understand which T cell subpopulations are important for protection and 
how do they differentiate. This knowledge will certainly contribute for the development of new and 
more effective vaccines against TB. 
 
1.6 TB prevention and treatment  
 
1.6.1 BCG vaccination 
BCG is currently the only available vaccine against TB. BCG is a live strain of Mycobacterium bovis 
developed in 1921 by Calmette and Guérin through consequent passages of a virulent strain of M. 
bovis that suffered attenuation [101, 102]. This vaccine is able to interact with different 
components of the innate and adaptive immune systems [101, 102]. Currently, BCG is 
administrated intradermally soon after birth. However, the efficiency of this vaccine is variable, 
ranging from 0 to 80%, and it only prevents the dissemination of disease in childhood, not avoiding 
the development of pulmonary TB in adulthood [101, 102]. The observed variation in BCG 
efficiency can be due to several factors like: early exposure to environmental mycobacteria, 
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differences in BCG sub-strains or in subsequent Mtb strains infecting the individual, inadequate 
stimulation of immune system by BCG, age of administration and host genetic variation [101, 102]. 
In addition, the protection conferred by BCG is limited and has the duration of 10 to 20 years [101, 
102]. However, a second immunization with BCG or other mycobacterial preparations may not be 
a good approach because repeated exposure of mice with previous latent Mtb infection, to 
mycobacterium antigens was shown to induce an exacerbated immune response leading to severe 
lung damage [94]. 
 
 1.6.2 The immune response underlying BCG vaccination 
Although BCG has been used for many years, being one of the most widely used vaccines in the 
world, our knowledge on the cellular and molecular mechanisms involved in the protection 
conferred by BCG is still limited [101].  
Achievement of BCG mediated protection, requires antigen-specific effector T cells to be recruited 
quickly to the site of infection and to activate the infected phagocytes [4, 103]. Furthermore, these 
cells should be able to persist within the infection site [104, 105].  
As discussed before, IFN--producing CD4+ T cells are essential for Mtb control and for the host 
survival [106, 107]. For this reason, IFN--producing T cells have been widely used as a correlate 
of protection upon Mtb infection [108, 109]. However, the level of IFN- production does not 
necessarily associate with vaccine mediated protection [108, 110], suggesting that other immune 
factors are also important for T cell-mediated protection. Indeed, it has been demonstrated that 
BCG vaccinated IFN--deficient mice, although limited, exhibit protection against a subsequent Mtb 
aerosol infection, in a mechanism dependent of CD4+ T cells [90, 110].  
Th17 cells have also been associated with vaccine-induced protection by anticipating Th1 arrival 
to the infected lung [83]. As explained before, Th17 cells increase the expression levels of 
chemokines responsible for attracting T cells, such as CXCL9, 10, and 11, which in turn enhance 
the recruitment of IFN--producing T cells to the site of infection [103]. Nevertheless, repeated 
exposure of mice, with a stabilized Mtb-infection, to BCG vaccination leads to an uncontrolled IL-
17 cellular response that induce tissue damage related with increased neutrophil recruitment to 
the lung [94].  
Clearly, CD4+ effector T cells comprise several T cell subsets, going from early activated T cells 
only producing IL-2, single cytokine secretors such as IFN-- or IL-17-producing T cells, to CD4+ T 
cells that might have several effector functions by the simultaneous secretion of various immune 
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factors such as IFN-, TNF and IL-2 [4]. The presence of these multifunctional T cells has been 
associated with protection in mouse models of Leishmania major infection [111]. Given that IFN- 
by itself was not associated with vaccine-induced protection, it is expected that CD4+ T cells 
secreting multiple cytokines might play an important function in the control of Mtb infection [108]. 
However, the protective role of these cells in TB still unclear [112]. Mtb-infected mice primed with 
BCG and boosted with Modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) showed 
a higher control of bacterial burden in the lungs that was associated with the presence of 
multifunctional T cells producing IFN-, TNF and IL-2 compared with BCG alone [108]. Also, studies 
of BCG vaccination with infants demonstrated the presence of T cells that secrete several 
combinations of IFN-, TNF and IL-2 [113]. However, another study reported that adults with active 
Mtb infection expressed higher multifunctional CD4+ T cells than individuals with latent disease 
[114]. This observation suggests that multifunctional CD4+ T cells might associate with active 
disease, instead of protective immunity. Moreover, it seems that the presence of CD4+ T cells 
secreting multiple cytokines correlates with bacterial load, as indicated by the reduction of 
multifunctional T cells in TB subjects after the end of TB therapy [114]. 
It has been reported that BCG immunization is less protective against Beijing Mtb strains when 
compared with H37Rv infection, a reference laboratory strain [19, 21]. In a study performed by 
Ordway et al. until day 30 post-aerosol infection, mice infected with Beijing strains were equally 
protected comparative to H37Rv-infected ones. However, at day 60 post-infection the protection 
conferred by BCG was lost in Beijing-infected mice. This observation suggests that BCG protection 
against the Beijing strains tested was only transient and fails in long term-protection. This raises 
the question that BCG immunization or other BCG-like vaccines could be unsuccessful in regions 
of the world with high prevalence of Beijing genotype strains [20]. In contrast, other study 
demonstrated no strain-specific differences in BCG-induced protection [115]. Also, in humans, 
some studies tried to correlate BCG inefficacy with Beijing endemic areas, while others failed in 
demonstrating such association [19]. In our laboratory, in a panel of Beijing Mtb strains, we found 
a Mtb strain that in addition to TLR2 also triggers TLR4, with an impact for the outcome of Mtb 
infection. Thus, in this thesis, we investigated whether BCG vaccination is equally effective in 
inducing protection against this Beijing TLR4-activating Mtb strain [34]. In addition, taking into 
account the particular feature of this Mtb strain we want to understand the role of TLR4 triggering 
on the development of CD4+ T cell responses evoked by BCG vaccination.  
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 1.6.3 Novel vaccination approaches 
The impairment of BCG vaccination in protecting the host against TB in addition to the emergence 
of drug resistant strains of Mtb highlights the urgency of alternative strategies for prevention and 
therapy. Therefore, it is of extreme importance understand the underlying mechanisms that 
mediate both natural and vaccine-induced immunity [116]. Several strategies have been 
implemented to develop a better vaccine against TB. However most of them are based on boosting 
the immune response to BCG, in order to improve their effectiveness. As explained before, BCG is 
not an ideal vaccine and the protection conferred is not life-long, although it can prevent the most 
severe childhood manifestations of TB [101, 102]. Thus, the achievement of a most effective 
vaccine against TB may require the development of a booster vaccine [101, 102]. For instance, 
BCG vaccination early in life followed by an adjuvant to increase the strength and the durability of 
an effective immune response [117].  
The most advanced of these improved vaccines is MVA85A that enhanced the protective efficacy 
of BCG in animal models by delivering the immunodominant antigen 85A as a booster using a 
replication-deficient poxvirus [118]. Recently, the phase IIb of clinical trials was completed but no 
significant protection against Mtb was obtained after MVA85A administration in infants [119].   
Adjuvants can be added to vaccines such as in Hepatitis A virus vaccine in order to enhance 
effective T cell responses. PAMPs, specifically those binding the TLRs, are the basis of many 
adjuvants [11]. Therefore, the new generation of vaccines often integrates agonists of TLRs to 
enhance T helper cell responses [120]. The glycolipid monophosphoryl lipid A (MPL ®), which 
activates TLR4, was the first TLR ligand used as adjuvant in an approved human vaccine (the 
Hepatitis B vaccine Fendrix ®) [120]. M72 consisting of Mtb72F polyprotein formulated with the 
adjuvant AS02A (a MPL® based adjuvant) has been tested as a TB candidate vaccine [117, 118]. 
M72 was administrated as a boost of BCG in the cynomolgus monkey model demonstrating 
superior protection than that afforded by using BCG alone [121]. Furthermore this vaccine was 
well tolerated by healthy adult subjects in a phase I clinical trial [118]. Another study showed that 
boosting of BCG with the recombinant fusion protein ID93, adjuvanted with the TLR4 agonist 
Glucopyranosyl Lipid Adjuvant (GLA), formulated in a stable oil-in-water emulsion (SE) (ID93+GLA-
SE), protects mice and guinea pigs against Mtb compared to BCG alone [122]. ID93+GLA-SE is 
presently under Phase I clinical trials [123]. 
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 1.6.4 TB treatment 
Since BCG is not effective in preventing TB, treatment with anti-TB drugs is mandatory. Generally 
the treatment of drug-sensitive Mtb stains can be performed with a combination of first line drugs 
which comprise isoniazid, rifampin, pyrazinamide and ethambutol for at least 6 months. However, 
if the therapy is not successful, for instance with MDR and XDR strains, a second line of anti-TB 
drugs such as kanamycin, amikacin, capreomycin, para-aminosalicyclic acid, cycloserine, 
prothionamide and thiacetazone has to be implemented for at least 2 years [124, 125].  
Therefore it is clear that alternative strategies for prevention and therapy are urgently needed to 
tackle the TB burden in the world.  
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Previous data from our laboratory demonstrated that different Mtb strains trigger different TLRs, 
with impact in both in vitro and in vivo immune responses. Using in vitro and in in vivo models of 
infection we showed that 02-171 Mtb strain from the Beijing lineage is recognized not only by 
TLR2, but can also trigger TLR4. In contrast, the reference strain H37Rv mainly activates TLR2. 
Interestingly, we observed that TLR4 deficiency led to a higher susceptibility of mice upon intranasal 
infection with 02-171 Mtb strain, whereas the same did not occur in H37Rv-infected mice, thus 
suggesting a protective role for TLR4 triggering [34]. Given that TLR activation could influence the 
differentiation of T cells [52, 53], which are fundamental for protection against TB [2, 4, 5, 56], in 
the Chapter I of this thesis we focus on the consequences, at the adaptive immune level, of TLR4 
activation during a primary mycobacterial infection by 02-171. Therefore the main goals of this 
chapter were to investigate: 
i) the role of TLR4 activation on T cell priming, activation and recruitment; 
ii) the consequence of TLR4 activation on the lung pathology and granuloma organization 
upon infection by 02-171 Mtb strain. 
 
Recent studies suggest that BCG is less effective to protect mice against infection with Beijing 
strains comparative to the strain H37Rv [19, 21]. Given that BCG is mainly recognized by TLR2 
[126], we speculated that the type of acquired immunity induced by BCG immunization may be 
protective against TLR2-activating Mtb strains, but defective towards a TLR4-activating Mtb strain 
challenge. Thus, we hypothesized that the differential TLR recognition of Mtb strains could also 
account for the variability of BCG protection. In this line, Chapter II focuses on the role of TLR4 
activation by 02-171 Mtb strain during a recall response after BCG vaccination. The main goals of 
this part of the work were to evaluate:  
i) the effectiveness of BCG vaccination in protecting WT mice against Mtb infection with 02-
171 Mtb strain; 
ii) the impact of TLR4 triggering in the effectiveness of BCG vaccination against TLR4-
activating Mtb strain infection; 
iii)  how TLR4 activation during Mtb infection influences BCG-induced CD4+ T cell responses. 
 
The knowledge of how natural and vaccine induced immunity generated in response to Mtb 
infection could have a huge impact on the development of new strategies of vaccination and 
therapy.  
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Animals 
WT C57BL/6 mice were purchased from Charles River (Barcelona, Spain). TLR4 deficient 
(TLR4−/−) mice were breed at the ICVS animal facility. NOS2 deficient (NOS2−/−) mice were 
kindly provided by Dr. Rui Appelberg, Institute for Molecular and Cell Biology (IBMC), University of 
Porto, Porto, Portugal. All mice were kept at the ICVS animal facility under conventional conditions, 
with food and water given ad libitum. Both male and female mice between the ages of 8 and 12 
weeks were used. All procedures involving animals were carried out in accordance with the 
European Union Directive 86/609/EEC, and previously approved by the Portuguese National 
authority Direcção Geral de Veterinária.  
 
Bacterial strains and growth conditions 
Mtb clinical isolate 02-171 was kindly provided by Dr. Gunilla Källenus Karolinska Institutet, 
Sweden and Mycobacterium bovis BCG Pasteur (hereafter simply referred as BCG) was originally 
from the Trudeau Institute Mycobacterial Collection. Bacteria were first grown at 37ºC in 
Middlebrook 7H9 Broth (BD Bioscience) for 7–10 days and then diluted into Proskauer Beck (PB) 
medium supplemented with 30% glycerol and 0.05% Tween 80. At mid-log phase bacterial stocks 
were collected and frozen in 1 mL aliquots at -80ºC.  
 
Experimental aerosol infection and BCG vaccination 
Mice were infected via the aerosol route by using an inhalation exposure system (Glas-Col) 
calibrated to deliver a dose of 100 to 200 colony forming units (CFUs) of Mtb 02-171. In some 
experiments a lower aerosol infection dose of nearly 70 CFUs was used. The mycobacterial 
inoculum was prepared from the frozen stock, firstly by passing it through a 26G needle 6 times 
to disrupt bacterial clumps and then diluted in water (Aqua B. Braun) to the desirable 
concentration. Then, 10 mL of this suspension were placed into the nebulizer and the mice were 
exposed to the aerosol cloud for 40 minutes. The infection dose was confirmed for every experiment 
by plating the entire lung 3 days after the aerosol infection, as described below.  
In some experiments, mice were subcutaneously vaccinated in the chest with 106 CFUs of BCG 
and rested for 90 days before Mtb aerosol infection. 
 
 
 
28 
 
Preparation of single cell suspensions 
At day 3 and selected time-points post-infection mice were killed by CO2 asphyxiation and the organs 
were aseptically excised. Lungs were first perfused with cold phosphate-buffered saline (PBS) 
through the right ventricle of the heart until the lungs appeared white, minced and incubated for 
30 minutes at 37ºC with collagenase IX (0.7mg/mL, from Sigma-Aldrich). Digested lungs, LN or 
livers were disrupted by passage through a 40-μm-pore-size nylon cell strainer (BD Biosciences). 
LN cells were resuspended in complete Dulbecco's Modified Eagle Medium (cDMEM, DMEM 
supplemented with 10% of heat-inactivated fetal bovine serum (FBS), 1% of HEPES, 1% L-glutamine 
and 1% sodium pyruvate (all from GIBCO) and used for bacterial burden determination. Liver cells 
were used for bacterial burden determination and lung suspensions were treated with a red blood 
cells lysis buffer (0.87% of NH4Cl solution and 5% of PBS in water) to remove red blood cells and 
resuspended in cDMEM. Lung single cell suspensions were enumerated with a Countess Automatic 
Cell Counter (Life Technologies).  
 
Bacterial Burden determination 
Bacterial burdens were determined by incubating single cell suspensions with 0.1% saponin 
(Sigma-Aldrich) for 10 minutes at room temperature (RT) to disrupt the cells that harbor Mtb. CFUs 
were determined by plating 10-fold serial dilutions of the disrupted cell suspensions in Middlebrook 
7H11 (BD Biosciences) agar plates supplemented with 10% oleic acid/albumin/dextrose/catalase 
(OADC) and 0.5% glycerol. BBL™ MGIT™ PANTA™ antibiotic mixture (BD Bioscience) was used to 
prevent contaminations. Viable mycobacteria colonies were enumerated after 3 weeks of 
incubation at 37ºC. Values were transformed in Log10 before plotting and statistically analyzed.  
 
Flow cytometry analysis of single cell suspensions 
For cell surface antigen staining antibodies against CD8-FITC (clone 5H10-1 from BioLegend); 
CD69-PerCP-Cy5.5 (clone H1.2F3 from BD Biosciences); CD4-APC-Cy7 (clone GK1.5 from 
BioLegend); CD3-PerCP-Cy5.5 (clone 145-2C11 from BioLegend); killer-cell lectin-like receptor G1 
(KLRG1)-APC (clone 2F1 from eBioscience); programmed cell death 1 (PD-1)-PECy7 (RMP1-30 
from BioLegend ) CD11b-PE (clone M1/70 from BioLegend); lymphocyte antigen 6G (Ly6G)-APC 
(clone 1A8 from BioLegend) were used. Single cell suspensions were first incubated with Fc block 
(BioLegend) for 10 minutes on ice and then stained in fluorescence-activated cell sorting (FACS) 
buffer (PBS containing 2% of FBS plus 0.01% of azide) for surface markers at 4ºC for 30 minutes. 
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Cells were then washed with FACS buffer, resuspended in PBS containing 2% of formol and kept 
overnight (ON) at 4ºC in the dark before analyzed.  
 
For intracellular cytokine staining, cell suspensions were restimulated with a mixture of phorbol 
myristate acetate (PMA) (50ng/mL) and ionomycin calcium salt (4μg/mL) for 4 hours, in the 
presence of brefeldin A (10μg/mL) (all from Sigma-Aldrich). For the detection of cytokine 
production, antibodies against TNF-FITC (clone MP6-XT22 from BioLegend); GM-CSF-PE (clone 
MP1-22E9 from eBioscience); INF--PE-Cy7 (clone XMG1.2 from eBioscience); IL-2-PB (clone 
JESG-5H4 from BioLegend) and IL-17-APC (clone TC11-18H10.1 from BioLegend) were used. 
Upon surface staining, cells were fixed and permeabilized with the Fixation/Permeabilization buffer 
(eBioscience) in the dark for 30 minutes at 4ºC. Cells were washed with the Permeabilization/Wash 
buffer (eBioscience) and incubated with a cocktail of fluorochrome-labeled antibodies at 4ºC for 30 
minutes, in the dark. Finally, cells were resuspended in PBS containing 2% of formol and kept ON 
at 4ºC in the dark. 
 
For Bromodeoxyuridine (BrdU) staining mice were subjected to an intraperitoneaI injection (IP) of 
0.8 mg of BrdU (Sigma-Aldrich) 24 hours before harvest. BrdU staining was performed with APC 
BrdU Flow Kit (BD Biosciences) according to the manufacturer's instructions. Briefly, after surface 
staining, cells were fixed and permeabilized using the BD Cytofix/Cytoperm buffer for 20 minutes 
at 4ºC in the dark. Cells were then washed with BD Perm/Wash buffer and resuspended in BD 
Cytofix/Cytoperm PLUS and incubated 10 minutes at 4ºC in the dark. After washing, cells were 
fixed again with the BD Cytofix/Cytoperm Buffer for 5 minutes at 4ºC in the dark, washed and 
incubated with DNAse (300µg/mL in PBS), to expose incorporated BrdU, for 1 hour at 37ºC in the 
dark. Cells were then washed and stained with anti-BrdU antibody (APC) for 30 minutes at RT in 
the dark. Finally, cells were resuspended in PBS containing 2% of formol and kept ON at 4ºC in the 
dark. 
 
Unstained cells were used to access autofluorescence and single stained controls were performed 
for fluorescence compensation. Samples were acquired on a LSRII flow cytometer (BD Bioscience). 
All data were analyzed using FlowJo software (TreeStar). The frequency of responding cells was 
determined and applied to the number of cells per sample to generate the total number of specific 
cell populations per organ. 
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RNA extraction and quantification 
Total lung RNA was extracted by using TRIzol® Reagent (Invitrogen, San Diego, CA) according to 
the manufacturer’s instructions. Briefly, glycogen (20μg/μL from Roche) was added to each 
sample and incubated for 5 minutes at RT. After incubation, 50µL of chloroform (Sigma-Aldrich) 
were added and the samples were mixed and incubated on ice for 15 minutes. After centrifuging 
at 13000 rpm for 15 minutes at 4ºC, the upper aqueous phase (containing RNA) was carefully 
transferred to a new tube, and mixed with an equal volume of isopropyl alcohol (Sigma-Aldrich) to 
precipitate the RNA. Samples were incubated ON at -20ºC and then centrifuged at 13000 rpm for 
15 minutes at 4ºC before removing the supernatant and washing the RNA pellet with 800µL of 
70% ethanol (Carlo Erba reagents). Ethanol was completely removed after centrifugation at 9000 
rpm for 5 minutes and the dried RNA pellet resuspended in RNase/DNase-free water (Gibco). RNA 
concentration was measured (Nanodrop ND-1000 Spectrophotometer) and purity assessed 
through the A260/A280 and A260/A230 ratios. 
 
cDNA synthesis and RT-PCR 
cDNA synthesis was performed with the RevertAid H minus kit (Fermentas life sciences) according 
to the manufacturers’ instructions. Briefly, 1µL of OligodT, 1µL of diethylpyrocarbonate (DEPC) 
water, 1μL of Riboblock, 1μL of Reverter Aid, 4μL of Reaction buffer and 2μL of dNTP per sample 
were mixed with 10μL of RNA sample. The cDNA synthesis reaction was performed in thermocycler 
(Bio-Rad) at 42ºC for 60 minutes following by 70ºC for 15 minutes. The resultant cDNA template 
was used for quantification of target genes by RT-PCR analysis with SYBR green or TaqMan 
detection systems. Ubiquitin or hypoxanthine phosphoribosyltransferase (HPRT) were used as 
housekeeping genes. For SYBR Green based reactions 1μL of cDNA sample was added to 9μL of 
RT-PCR mix that contains 3μL of water, 1μL of forward and reverse primer and 5μL of SYBR green 
(Qiagen). RT-PCR was carried out in thermocycler (Bio-Rad) using the following cycling parameters: 
95ºC for 15 min, followed by 40 amplification cycles of 95ºC for 15 seconds, 58ºC for 20 seconds 
and 70ºC for 15 seconds, and the melting curve analysis.  
For TaqMan based reactions 1μL of cDNA sample was added to 9μL of RT-PCR mix that contains 
3.5μL of water, 0.5μL of primers and 5μL of TaqMan Gene Expression Master Mix (Applied 
Biosystems). RT-PCR was carried out in thermocycler (Bio-Rad) using the following cycling 
parameters: 50ºC for 2 minutes, 95ºC for 10 minutes, 40 cycles of 95ºC for 15 seconds and 60ºC 
for 1 minute, followed by 60ºC for 1 minute. 
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Relative mRNA expression of the gene of interest was normalized to the levels of the housekeeping 
gene using the Ct method:  
1.8 (Housekeeping gene mRNA expression – Target gene mRNA expression) x 100000 
A control without template was done in parallel. The sequences of primers and the references of 
the TaqMan primer-probe sets used in RT-PCR are listed in Table I and II, respectively. 
 
Histology and immunohistochemistry 
The right upper lobe of the lung was inflated with 10% neutral buffered formalin and submerged 
during a week at 4ºC in the same solution before to be embedded in paraffin. 
For histological analysis sections of 3µm thickness stained by hematoxylin and eosin (H&E) were 
processed routinely by light microscopy. For immunofluorescence staining of iNOS, tissue sections 
of 3µm thickness were desparaffinized with xylene and rehydrated in steps from absolute ethanol 
to distilled water. Antigens were retrieved using Citrate buffer (Thermo Scientific) in a 96ºC pre-
warmed water bath for 30 minutes. The sections were then washed for 5 minutes with PBS solution 
containing 0.1% (v/v) Triton X-100 and 0.1% Tween-20. From here on, incubation periods were 
carried out in a humidified chamber to prevent tissue sections drying. Tissue sections were blocked 
for one hour at RT with 0.1% (v/v) Triton X-100, 0.1% Tween-20 and 5% bovine serum albumin 
(BSA) (Sigma-Aldrich) in PBS and incubated ON at 4ºC with a goat anti-mouse NOS2 antibody (M-
19G, Santa Cruz) followed by an Alexa Fluor 568-conjugated polyclonal rabbit anti-goat (Invitrogen), 
for one hour at RT, in the dark. Finally, slides were mounted using Vectashield mounting medium 
containing DAPI (49,6-diamino-2-phenylindole hydrochloride) (Invitrogen), to stain nuclei. 
Representative images were obtained with an Olympus BX61 microscope and were recorded with 
a digital camera (DP70) using the cell^P software. The immunohistochemistry images were 
processed using ImageJ software. 
 
Statistical analysis 
The results are given as means ± standard error of the mean (SEM) of at least four animals for 
experimental group, as indicated in the figure legends. Differences between means were analyzed 
by two-way Analysis of variance (ANOVA) with Bonferroni post-hoc test in Graph Pad Prism 5 
software. Values were considered significant for p≤0.05 and defined as *, p≤0.05; **, p≤0.01 and 
***, p≤0.001. 
32 
 
Table I – Sequences of the SYBR Green specific oligonucleotides for ubiquitin and target genes 
used for quantification of mRNA expression by RT-PCR.  
 
GENES PRIMERS SEQUENCE 
Ubiquitin 
Sense 5’- TGGCTATTAATTATTCGGTCTGCAT -3’ 
Anti-sense 5’- GCAAGTGGCTAGAGTGCAGAGTAA -3’ 
IL-17 
Sense 5’- CTCAGACTACCTCAACCGTTCCA -3’ 
Anti-sense 5’- TTCCCTCCGCATTGACACA -3’ 
TNF 
Sense 5’-GCCACCACGCTCTTCTGTCT-3’ 
Anti-sense 5’-TGAGGGTCTGGGCCATAGAAC-3’ 
IL-12b (p40) 
Sense 5’- CAAATTACTCCGGACGGTTC -3’ 
Anti-sense 5’- AGAGACGCCATTCCACATGTC -3’ 
IL-23a (p19) 
Sense 5’- CGTATCCAGTGTGAAGATGGTTGT -3’ 
Anti-sense 5’- GCTCCCCTTTGAAGATGTCAGA -3’ 
  
 
Table II – References of the TaqMan primer-probe sets for HPRT and target genes used for 
quantification of mRNA expression by RT-PCR. 
 
GENES PRIMER-PROBE SET REFERENCE (APPLIED BIOSYSTEMS) 
IFN- Mm01168134_m1 
NOS2 Mm00440502_m1 
CXCL9 Mm00434946_m1 
CXCL10 Mm 99999072_m1 
CXCL11 Mm00444662_m1 
HPRT Mm00446968_m1 
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RESULTS – CHAPTER I 
 
IMPACT OF TLR4-TRIGGERING ON T CELL RESPONSES DURING A PRIMARY INFECTION 
WITH A TLR4-ACTIVATING MTB STRAIN 
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1.1 Activation of TLR4 by 02-171 Mtb strain during primary infection impacts the 
frequency but not the number of CD4+ T cells in the lungs 
Previous data from our laboratory demonstrated that different strains of Mtb trigger different TLRs 
[34]. Using in vitro and in in vivo models of infection, we showed previously that 02-171 Mtb strain 
from the Beijing lineage besides being recognized by TLR2 also triggers TLR4, comparatively to 
H37Rv that preferentially activates TLR2. Importantly, this differential recognition of Mtb strains 
impacts both in vitro and in vivo immune responses [34]. Moreover recombination-activating gene 
(Rag)2 -/- mice infected via the intranasal route with Mtb strain 02-171 succumbed earlier than 
H37Rv-infected ones and exhibited higher bacterial loads in the lungs at day 30 post-infection, 
suggesting that, despite the increased virulence of 02-171 during the innate phase of the immune 
response, an efficient and protective T cell response was differentiated in response to Mtb 02-171 
[34].  
Thus, to further understand the impact of TLR4-triggering on T cell response during a primary 
infection, we infected WT and TLR4 -/- mice via the aerosol route with a low dose of 02-171 Mtb 
strain, a TLR4-activating strain. 
We firstly compared the presence of CD4+ and CD8+ T lymphocytes in the lungs of WT and TLR4 
-/- 02-171-infected mice by flow cytometry. As expected, the total number of CD4+ and CD8+ T 
cells in the lungs only increased from day 20 post-infection (Figure 1B and C) which coincides with 
the arrival to and accumulation of T cells in the infected lungs. Interestingly, at day 25 post-infection 
we observed an increased frequency of CD4+ T cells in the lungs of WT mice compared with TLR4 
-/- 02-171-infected mice (Figure 1A and B). However, this difference was not translated to the total 
number of this T cell population (Figure 1B). Furthermore, the frequency and the total number of 
CD8+ T cells in the lungs were similar in both strains of mice (Figures 1A and C), indicating that 
TLR4 activation did not impact CD8+ T cell responses. 
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Figure 1 – TLR4 triggering by 02-171 Mtb strain impacts the frequency of CD4+ T cells at day 25 post-
infection. WT (circles) and TLR4 -/- (squares) mice were infected with Mtb strain 02-171 via the aerosol route with a 
low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean ± SEM for 4 animals)). Infected mice were euthanized at the 
indicated time points after infection. Lung cell suspensions were prepared and the CD4+ and CD8+ T cells were 
analyzed by flow cytometry. (A) Representative FACS profile showing CD4 and CD8 expression by lung cells at day 25 
post-infection. The Mean ± SEM of CD4+ and CD8+ cells of each experimental group is indicated. (B) Percentage and 
total number of CD4+ cells in the lung. (C) Percentage and total number of CD8+ cells in the lung. The data points 
represent the Mean ± SEM of at least four mice per group and the statistical significance was determined by Two-way 
ANOVA with Bonferroni post-test. Data are from one experiment. (***, p≤0.001) 
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1.2 The increased frequency of CD4+ T cells in the lungs of WT 02-171-infected mice 
was not due to cell proliferation at the site of infection. 
Given that we observed a higher frequency of CD4+ T cells in the lungs of WT mice compared to 
TLR4 -/- 02-171-infected mice, we questioned whether it was due to higher proliferation of this T 
cell population in the lungs of WT 02-171-infected mice. In order to assess the proliferation of 
CD4+ and CD8+ T cells, 24 hours prior the experimental time point, WT and TLR4 -/- 02-171-
infected mice were injected with BrdU intraperitoneally, and the percentage of BrdU positive cells 
– that are actively synthesizing DNA – was determined for each T cell population by flow cytometry 
(Figure 2). The total number of BrdU positive cells (Figure 2) increased during the course of 
infection indicating that both CD4+ and CD8+ T cells proliferated in the infected lungs. However, 
there were no marked differences in the proliferation of CD4+ or CD8+ T cells in WT or TLR4 -/- 
02-171-infected mice (Figures 2A and B), suggesting that local T cell proliferation does not account 
for the difference observed in the frequency of CD4+ T cells in WT versus TLR4 -/- infected lungs 
(Figure 1B).  
 
 
 
Figure 2 – Cell proliferation was not responsible for the increased frequency of CD4+ T cells in the 
lungs of WT 02-171-infected mice. WT (circles) and TLR4 -/- (squares) mice were infected with Mtb strain 02-
171 via the aerosol route with a low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean ± SEM for 4 animals)). 
Infected mice were euthanized at indicated time points after infection. Twenty-four hours before the harvesting, mice 
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were subjected to an IP injection containing 0.8mg of BrdU (100µL/mouse). Lung cell suspensions were prepared 
and the levels of cell-associated BrdU were measured by flow cytometry. The frequency and total number of BrdU 
positive cells were analyzed either in CD4+ T cells (A) or in CD8+ T cells (B). Representative FACS profile of BrdU 
expression among CD4+ or CD8+ T cells at day 25 post-infection. The Mean ± SEM of BrdU positive cells of each 
experimental group is indicated (left panels). The data points represent the Mean ± SEM of at least four mice per group 
and the statistical significance was determined by Two-way ANOVA with Bonferroni post-test. Data are from one 
experiment. 
 
1.3 Increased expression of Cxcl10 and Cxcl11 in 02-171-infected WT mice 
compared to TLR4 -/- mice 
Exposure to mycobacteria antigens elicits effector T cell differentiation in local LN, followed by 
migration of activated T cells to and within the site of infection [4]. In the LN, T cells become 
activated and committed to a specific lineage such as Th1 or Th17 cells, increasing in their cell 
surface the expression of specific receptors as CXC chemokine receptor 3 (CXCR3), C-C chemokine 
receptor 5 (CCR5) and CCR2 [127]. CXCR3 binds to specific chemokines as CXCL9, CXCL10 and 
CXCL11 [127]. The expression of these chemokines is associated with the increased recruitment 
of Th1 cells to the local of infection [127]. 
Our previous results demonstrated that the increased frequency of CD4+ T cells in the lungs of WT 
02-171-infected mice comparative to TLR4 -/- mice was not due to local proliferation. Next, we 
investigated if the difference observed was a consequence of differential recruitment of T cells to 
the infected lungs. To address that, we analyzed by RT-PCR the relative mRNA expression levels of 
CXCR3 specific chemokines namely CXCL9, CXCL10 and CXCL11 (Figure 3). The expression of 
these Th1 cell recruiting chemokines was increased in the infected lungs as early as 20 days post-
infection which coincides with the arrival to and accumulation of T cells in the infected lungs (Figure 
1B). Consistent with the higher frequency of CD4+ T cells at day 25 post-infection in WT-infected 
mice compared to TLR4 -/- mice, the relative mRNA expression levels of Cxcl10 (Figure 3B) and 
Cxcl11 (Figure 3C) at day 20 post-infection were significantly higher in the lungs of WT-infected 
mice than in TLR4 -/- -infected ones. Although not statistically significant, the levels of Cxcl9 were 
also higher in WT than in TLR4 -/- infected lungs (Figure 3A). Therefore, these findings suggest 
that the increased frequency of CD4+ T cells in WT mice could be due to the differential expression 
of chemokines in the lungs of WT and TLR4 -/- -infected mice, which would contribute to a 
differential recruitment of these cells.  
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Figure 3 – Chemokines responsible for attracting T cells were differentially expressed in the lungs of 
WT and TLR4 -/- mice during 02-171 Mtb infection. WT (black bars) and TLR4 -/- (white bars) mice were 
infected with Mtb strain 02-171 via the aerosol route with a low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean 
± SEM for 4 animals)). Mice were euthanized at indicated time points after infection. Total RNA was extracted from 
lung homogenates and the relative mRNA expression of Cxcl9 (A), Cxcl10 (B) and Cxcl11 (C) was analyzed by RT-
PCR and normalized to the expression of Hprt. Data represented for day 0 correspond to uninfected animals. Data 
represent the Mean ± SEM of at least four mice per group and the statistical significance was determined by Two-way 
ANOVA with Bonferroni post-test. Data are from one experiment. (*, p≤0.05; ***, p≤0.001)  
 
1.4 TLR4 triggering by 02-171 Mtb strain does not impact the phenotype of CD4+ T 
cells generated during infection 
In addition to the frequency of CD4+ T cells present in the infected lungs, their specific phenotype 
is also determinant for the protection offered by these cells. For this reason, we next investigated 
whether TLR4 triggering by a TLR4-activating Mtb strain influenced the phenotype of CD4+ T cells. 
For that, lung cell suspensions were stained for the surface markers CD69, KLRG-1 and PD-1 and 
their expression levels analyzed by flow cytometry. CD69 expression has been used as a marker 
for early T cell activation [10]. During Mtb infection, KLRG1 expressing T cells have a higher ability 
to produce cytokines, but low proliferative capacity identifying terminally differentiated cytokine-
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producing effector T cells. On another hand, PD-1 positive T cells are activated effector cells, less 
differentiated, with high proliferative and low cytokine production ability [105, 128]. 
We observed that the number of CD4+ T cells expressing these activation markers at the infection 
site started to increase around 20 days post-infection (Figure 4). While the number of CD4+ T cells 
expressing CD69 and PD-1 still increased at least until day 32 post-infection (Figures 4A and C), 
CD4+ T cells expressing KLRG1, increased from day 20 of infection, achieved the peak at day 25 
post-infection and their expression stabilized until day 32 post-infection (Figure 4B).  Furthermore, 
we found similar expression of CD69, KLGR-1 and PD-1 in CD4+ gated T cells of WT or TLR4 -/- 
02-171-infected mice (Figures 4A, B and C), supporting no role for TLR4 activation on the 
phenotypic activation of CD4+ T cells, at least for the markers tested. 
 
 
 
Figure 4 – Absence of TLR4 signaling during 02-171 Mtb infection does not impact the phenotype of 
CD4+ T cells. WT (circles) and TLR4 -/- (squares) mice were infected with Mtb strain 02-171 via the aerosol route 
with a low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean ± SEM for 4 animals)). Infected mice were euthanized 
at indicated time points after infection. Lung cell suspensions were prepared and the phenotype of CD4 positive cells 
was assessed by flow cytometry. Total numbers of CD4+ T cells positive for CD69 (A), KLRG1 (B) or PD-1 (C) are 
shown. The data points represent the Mean ± SEM of at least four mice per group and the statistical significance was 
determined by Two-way ANOVA with Bonferroni post-test. Data are from one experiment.  
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1.5 TLR4 activation does not impact IFN- production by CD4+ T cells in the lung of 
02-171-infected mice 
To obtain further insight into the impact of TLR4 activation during Mtb infection on the phenotype 
of lung CD4+ T cells, we analyzed the ability of CD4+ T cells from WT or TLR4 -/- mice infected 
with Mtb strain 02-171 to produce IFN- and IFN- plus TNF by flow cytometry. We observed no 
marked differences in percentage and also in total number of IFN-+- (Figure 5A) and IFN-+TNF+-
producing CD4+ T cells from infected lungs (Figure 5B). Furthermore, both T cell populations 
peaked at day 25 post-infection and then their expression decreased (Figures 5A and B). An 
exception to this observation was the dynamics of the number of IFN--producing CD4+ T cells that 
upon 25 days after Mtb infection the expression was maintained relatively constant (Figure 5A).  
We also determined by RT-PCR the relative mRNA expression levels of IFN- and TNF cytokines in 
the total lung of infected mice. We observed that the expression of Ifng and Tnf increased after 20 
days of infection (Figures 5C and D). There were no significant differences in the amounts of Ifng 
or Tnf expression in the presence or absence of TLR4 signaling until day 25 post-infection (Figures 
5C and D). However, at day 32 post-infection TLR4 -/- mice exhibited higher expression of Ifng 
compared to WT-infected ones (Figure 5C). This could be indicative that in TLR4 -/- mice other cell 
types must contribute for the overall production of IFN-. 
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Figure 5 – TLR4 absence does not impact IFN- response in lung CD4+ T cells during 02-171 infection. 
WT (circles/black bars) and TLR4 -/- (squares/white bars) mice were infected with Mtb strain 02-171 via the aerosol 
route with a low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean ± SEM for 4 animals)). Mice were euthanized at 
indicated time points after infection. (A and B) Lung cell suspensions were prepared and cytokine production analyzed 
by flow cytometry. (A) Representative FACS profile of IFN- at day 25 post-infection. The Mean ± SEM of IFN- positive 
cells of each experimental group is indicated (left panel). Percentage and total number of IFN--producing CD4+ T cells 
(middle and right panels). (B) Representative FACS profile of IFN-+TNF+ at day 25 post-infection. The Mean ± SEM 
of IFN-+TNF+ cells of each experimental group is indicated (left panel). Percentage and total number of IFN-+TNF+ 
cells on gated CD4+ T cells (middle and right panels). (C and D) Total RNA was extracted from lung homogenates 
and the relative mRNA expression of Ifng (C) and Tnf (D) were analyzed by RT-PCR and normalized to the expression 
of Hprt or ubiquitin as indicated. Data represented for day 0 correspond to uninfected animals. Data represent the 
Mean ± SEM of at least four mice per group and the statistical significance was determined by Two-way ANOVA with 
Bonferroni post-test. Data are from one experiment. (*, p≤0.05) 
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1.6 TLR4 activation impacts IL-17 production by CD4+ T cells in the lung of 02-171-
infected mice 
In addition to IFN--producing T cells upon Mtb infection, IL-17-producing T cells are also induced 
[80]. For that reason, we next analyzed by flow cytometry the production of IL-17 or of IL-17 plus 
TNF by CD4+ T cells from WT or TLR4 -/- mice infected with Mtb strain 02-171. We found that 
although the production of IFN- by CD4+ T cells of 02-171 infected mice was not significantly 
altered (Figure 5A), the frequency of lung IL-17-producing CD4+ T cells was significantly increased 
in TLR4 -/- infected mice compared with WT-infected mice at days 20 and 25 post-infection (Figure 
6A). However, these differences were not reflected to the total number of IL-17-producing CD4+ T 
cells (Figure 6A). Moreover, at day 25 post-infection we observed a transient increase in the 
frequency and in the cell number of IL-17+TNF+ -producing CD4+ T cells in TLR4 -/- infected mice 
compared with WT mice (Figure 6B). We also determined by RT-PCR the relative mRNA expression 
levels for Il17 in the lungs of infected mice. We did not observe any significant difference in the 
total Il17 mRNA expression (Figure 6C) between WT and TLR4 -/- infected mice. This is in contrast 
to what was observed by flow cytometry, which may be explained by the contribution of other cell 
types for the production of IL-17. Since that IL-23 is fundamental for the maintenance of IL-17-
producing T cells [80, 91, 93] we also analyzed by RT-PCR the two subunits of this heterodimeric 
cytokine namely Il23a and Il12b [91]. In accordance with Il17 mRNA expression, we did not 
observe differences in the relative mRNA expression of Il23a (p19) and Il12b (p40) (Figure 6D and 
E), suggesting that TLR4 activation does not appear to influence the expression of IL-23.  
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Figure 6 – TLR4 deficiency influences the frequency of lung IL-17 CD4+ T cell response. WT 
(circles/black bars) and TLR4 -/- (squares/white bars) mice were infected with Mtb strain 02-171 via the aerosol route 
with a low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean ± SEM for 4 animals)). Mice were euthanized at 
indicated time points after infection. (A and B) Lung cell suspensions were prepared and cytokine production analyzed 
by flow cytometry. (A) Representative FACS profile of IL-17 at day 25 post-infection. The Mean ± SEM of IL-17 positive 
cells of each experimental group is indicated (left panel). Percentage and total number of IL-17-producing CD4+ T cells 
(middle and right panels). (B) Representative FACS profile of IL-17+TNF+ at day 25 post-infection. The Mean ± SEM 
of IL-17+TNF+ positive cells of each experimental group is indicated (left panel). Percentage and total number of IL-
17+TNF+ CD4+ T cells (middle and right panels). (C-E) Total RNA was extracted from lung homogenates and the 
relative mRNA expression of Il17 (C), Il23a (D) and Il12b (E) were analyzed by RT-PCR and normalized to the 
expression of ubiquitin. Data represented for day 0 correspond to uninfected animals. Data represent the Mean ± SEM 
of at least four mice per group and the statistical significance was determined by Two-way ANOVA with Bonferroni post-
test. Data are from one experiment. (*, p≤0.05; **, p≤0.01) 
 
1.7 Activation of TLR4 by 02-171 Mtb strain during primary infection does not impact 
lung neutrophil accumulation neither lung inflammation 
It has been reported that IL-17 production induces early neutrophil recruitment that might lead to 
tissue damage in cases of exacerbated IL-17 response [80]. Since we observed an increased 
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frequency of IL-17-producing CD4+ T cells in TLR4 -/- mice comparatively to WT infected mice, we 
next investigated the consequences of this increment for the lung inflammatory response. Thus, 
firstly we assessed the neutrophil accumulation in the lungs by flow cytometry. The frequency and 
total number of neutrophils (CD11b+Ly6G+ cells) were statistically similar between WT and TLR4 
-/- 02-171-infected mice (Figure 7A), although apparently higher in TLR4 -/- mice at day 25 post-
infection. It is thus possible that the increase in IL-17 impacts lung neutrophil recruitment, albeit 
at the time points tested this did not reach statistical significance.  
We also evaluated the role of TLR4 signaling on lung inflammation. For that, lung sections of the 
upper right lobe of infected mice were stained with H&E and analyzed. At day 20 post-infection we 
observed the appearance of small granulomata. From this time point onwards, the inflammatory 
infiltrates become more intense, until day 32 when we ended the experiment (Figure 7B). In 
accordance with the neutrophils counts, we did not observe significant differences in lung 
inflammation between WT and TLR4 -/- infected mice for the analyzed time points (Figure 7B). 
However, a quantitative analysis needs to be performed to achieve definitive conclusions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – TLR4 triggering by 02-171 Mtb strain does not impact lung neutrophil accumulation neither 
lung inflammation. WT (circles) and TLR4 -/- (squares) mice were infected with Mtb strain 02-171 via the aerosol 
route with a low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean ± SEM for 4 animals)). Mice were euthanized at 
indicated time points after infection. (A) Lung cell suspensions were prepared and the neutrophils were analyzed by 
the CD11b and Ly6G expression by flow cytometry. Representative FACS profile of neutrophils (CD11b+Ly6G+) at day 
25 post-infection. The Mean ± SEM of CD11b+Ly6G+ cells of each experimental group is indicated (left panel). 
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Percentage and total number of CD11b+Ly6G+ cells in the lung (middle and right panels). The data points represent 
the Mean ± SEM of at least four mice per group and the statistical significance was determined by Two-way ANOVA 
with Bonferroni post-test. (B) To assess lung inflammation the upper right lobes of the lung were excised from WT (top 
panel) or TLR4 -/- (bottom panel) mice and fixed lung sections were stained with H&E. Representative images from 
each experimental group were obtained. Images represented for day 0 correspond to uninfected animals. Data are 
from one experiment. 
 
1.8 TLR4 activation by 02-171 Mtb strain does not impact Nos2 expression  
Since we have previously described that upon intranasal infection with 02-171 Mtb strain the TLR4 
deficiency compromises NOS2 expression at gene and protein level [34], we next questioned if we 
also obtained this difference using the aerosol model and a low dose of infection. For that, we 
measured the induction of NOS2 in lung homogenates at gene expression level by RT-PCR and in 
lung tissues at protein level by immunofluorescence.  
As previously reported, we observed an increased expression of NOS2 during the progression of 
infection (Figure 8). Furthermore, we only detected considerable levels of NOS2 both at gene and 
protein level from day 20 post-infection (Figures 8A and B) which coincides with the accumulation 
of IFN--producing cells in the lung (Figures 5A and C). In contrast with what we found before using 
intranasal model of infection [34], we observed statistically similar levels of Nos2 expression (Figure 
8A) and NOS2 protein (Figure 8B) in both groups of Mtb-infected mice, although apparently higher 
in WT mice at day 20 post-infection (Figures 8A and B). However, a quantitative analysis needs to 
be performed to achieve definitive conclusions. Given that IFN- and TNF signaling synergize to the 
induction of NOS2 during Mtb infection [5, 56], our data is in line with our previous findings that 
IFN- and TNF were also not affected in the absence of TLR4 (Figure 5A, C and D). 
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Figure 8 – TLR4 triggering by 02-171 Mtb strain does not impact Nos2 mRNA neither NOS2 protein 
expression. WT (circles) and TLR4 -/- (squares) mice were infected with Mtb strain 02-171 via the aerosol route with 
a low dose of infection (Log10 (CFUs) 2.155 ± 0.015 (Mean ± SEM for 4 animals)). Mice were euthanized at indicated 
time points after infection. (A) Total RNA was extracted from lung homogenates and the relative mRNA expression of 
Nos2 was analyzed by RT-PCR and normalized to the expression of Hprt. Data represented for day 0 correspond to 
uninfected animals. Data represent the Mean ± SEM of at least four mice per group and the statistical significance 
was determined by Two-way ANOVA with Bonferroni post-test. (B) The upper right lobes of the lung were excised from 
WT (top panel) or TLR4 -/- (bottom panel) mice and lung sections were used to detect NOS2 protein by 
immunofluorescence. Images were obtained with 4x magnification and were representative from each experimental 
group. NOS2 protein (red) and DAPI (blue). Images represented for day 0 correspond to uninfected animals. Data are 
from one experiment. 
 
1.9 TLR4 deficiency does not compromise protection against an aerosol infection 
with a low dose of TLR4-activating 02-171 Mtb strain 
We have reported that the absence of TLR4 led to an increased bacterial burden in the lungs of 
02-171 intranasally infected mice. The same did not occur for H37Rv intranasally infected mice, 
which suggested a protective role for TLR4 activation upon infection with a TLR4-activating Mtb 
strain [34].  
Taking into account that upon aerosol infection with a low dose of 02-171 we did not observe 
differences in the expression of protective cytokines (e.g. IFN- and TNF) neither in Nos2 expression 
in WT and TLR4 -/- mice, we determined the bacterial burdens in the lungs and in the LN of WT 
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and TLR4 -/- mice after aerosol infection with 02-171 Mtb strain. This would help to elucidate if 
the loss of differences among the intranasal and aerosol infections could be reflected in the 
progression of infection in those mice. 
As published before, the bacterial burden in the lung of Mtb-infected mice increases exponential 
until arrival of T cells to the local of infection [4], which happens around 14 days post-infection. 
Then, the bacterial growth slows with the accumulation of T cells [4] which in our experiment 
occurred between day 14 and 20 post-infection (Figure 9A), and finally reached a stable plateau 
around day 30-32 post-infection (Figure 9A). In the LN the bacterial burden peaked at day 20 post-
infection, which might suggest the dissemination of the mycobacteria from the lung to the LN and 
the initiation of the T cell priming (Figure 9B). We did not observe any difference in the bacterial 
burden in the lungs and LN between TLR4 -/- and WT aerosol 02-171-infected mice (Figures 9A 
and B). Although these data are in apparent contrast with our previous work [34], these conflicting 
results can possibly be explained by the different route of infection (intranasal vs aerosol) and/or 
by the initial inoculum dose (low vs high infection dose). 
 
 
Figure 9 – TLR4 deficiency does not impact bacterial growth after aerosol infection with 02-171 Mtb 
strain. WT (circles) and TLR4 -/- (squares) mice were infected with Mtb strain 02-171 via the aerosol route with a low 
dose of infection. Infected mice were euthanized at indicated time points after infection and serial dilutions of lung (A) 
and LN (B) homogenates were plated and the bacterial burden were determined after 21 days of incubation. The 
initial infection dose in the lungs was Log10 (CFUs) 2.155±0.015 (Mean ± SEM for 4 animals). The data points represent 
the Mean ± SEM of at least four mice per group and the statistical significance was determined by Two-way ANOVA 
with Bonferroni post-test. Data are from one experiment. 
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1.10 Initial infectious dose impacts susceptibility of NOS2 -/- mice to the 02-171 Mtb 
infection 
We hypothesized that the higher susceptibility observed in TLR4 -/- mice compared with WT mice 
intranasally infected with 02-171 can be due to the inoculum dose, since the initial bacterial burden 
in the lungs of mice infected via the intranasal route was higher 380.19 ± 2.69 CFUs per mice 
(Mean ± SEM for 6 animals) [34] than in the experiment reported in this work 143.25 ± 5.14 CFUs 
per mice (Mean ± SEM for 4 animals) (Figure 9A). 
We have data in our laboratory from WT and NOS2 -/- mice which are in agreement with our 
hypothesis. WT and NOS2 -/- mice were infected via the aerosol route with different doses of 02-
171 Mtb strain by modulating the concentration of bacteria placed in the nebulizer. At day 3 post-
infection mice were sacrificed to determine the initial dose of bacteria delivered to the lung. The 
group of mice with the lowest dose was exposed to a Log10 (CFU) 1.814±0.049 (Mean ± SEM for 4 
animals) corresponding to an average of 66.50 ± 7.96 CFUs per mice (Figure 10A) and the group 
of mice with the standard dose was exposed to a Log10 (CFUs) 2.008±0.048 (Mean ± SEM for 5 
animals) that correspond to an average of 104.00 ± 11.10 CFUs per mice (Figure 10B). NOS2 -/- 
mice infected with the higher inoculum were less protected than WT mice as soon as 18 days post-
infection (Figure 10B). Whereas, with the lower inoculum dose NOS2 -/- mice only became more 
susceptible than WT 02-171-infected mice at day 31 post-infection (Figure 10A). These 
observations support our hypothesis that the inoculum size can influence the outcome of in vivo 
infection of mice with the TLR4-activating 02-171 Mtb strain. Of note, another major difference is 
the route of infection, which we have still to experimentally address. 
 
 
 
Figure 10 – Higher infectious dose results in higher susceptibility of NOS2 -/- mice to the 02-171 Mtb 
infection. WT (circles) and NOS2 -/- (inverted triangles) mice were infected with Mtb strain 02-171 via the aerosol 
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route with a low dose of infection. Infected mice were euthanized at indicated time points after infection and serial 
dilutions of lung homogenates were plated and the bacterial burden were determined after 21 days of incubation. The 
initial infection dose in the lungs in (A) and (B) was Log10 (CFUs) 1.814±0.049 (Mean ± SEM for 4 animals) and Log10 
(CFUs) 2.008±0.048 (Mean ± SEM for 5 animals), respectively. The initial infection dose was statistical different with 
p≤0.05 (p=0.0352). The data points represent the Mean ± SEM of at least four mice per group and the statistical 
significance was determined by Two-way ANOVA with Bonferroni post-test. Data are from one experiment. (*, p≤0.05; 
***, p≤0.001) 
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RESULTS – CHAPTER II 
 
EFFICACY OF BCG VACCINATION UPON INFECTION WITH A TLR4-ACTIVATING MTB 
STRAIN: ROLE OF TLR4 ACTIVATION DURING SECONDARY INFECTION  
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It is well established that protection conferred by BCG against pulmonary TB is highly variable [101, 
102]. Moreover, based on increasing evidences on the genetic heterogeneity and phenotypic 
differences among Mtb strains [15, 129], it was hypothesized that differences in strain genetics 
could also be partly responsible for the variation in BCG efficacy. In support of this hypothesis, 
recent studies have shown that BCG is less effective to protect mice against challenge with certain 
Beijing strains than with the laboratory strain H37Rv [19, 21].  
Considering the role of TLRs in shaping acquired immunity [52, 53], we hypothesized that the 
differential TLR recognition of Mtb strains, which we defined as a molecular basis for heterogeneous 
immune responses to Mtb, may also be the basis for the variable efficacy of BCG. 
 
2.1 BCG vaccination protects WT mice against an infection by a Beijing TLR4-
activating Mtb strain 
Given that BCG is mainly recognized by TLR2 [126], we speculated that the type of acquired 
immunity induced by BCG immunization may be protective against TLR2-activating Mtb strains, as 
H37Rv, but defective towards a TLR4-activating Mtb strain challenge. To test our hypothesis that 
the differential TLR recognition of Mtb strains could also account for the variability of BCG 
protection, we vaccinated WT mice with BCG 90 days prior to 02-171 Mtb strain challenge, a period 
of time that was previously shown in our laboratory to confer optimal protection against H37Rv 
infection (A. Cruz et al., submitted for publication).  
At specific time points post-infection, mice were sacrificed and the bacterial burden were 
determined after 21 days of incubation, by plating serial dilutions of lung and liver homogenates. 
As shown in Figure 11A, BCG vaccinated mice were protected against aerosol infection with 02-
171 Mtb, as shown by the reduction of bacterial burden in the lungs, the primary site of infection. 
The protection was also observed in the liver that represents a local of dissemination of Mtb 
infection (Figure 11B). BCG vaccination limited the bacterial growth in the lungs and in the liver as 
soon as 14 days post-infection (Figure 11A and B), similarly to the protection obtained for Mtb 
infection in other reported experimental mouse models [103]. This suggests that BCG vaccination 
accelerates the protective T cell response, causing an early limitation of 02-171 bacterial expansion 
as it has been reported for H37Rv [103]. Moreover, we found that BCG immunization can maintain 
long-lasting control of 02-171 Mtb strain infection since the infection remained controlled at day 
90 post-infection, being the bacterial burden in the lungs of vaccinated mice significantly lower 
than that exhibited by unvaccinated mice (Figure 11A). These findings indicate that BCG 
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vaccination can protect WT mice against an infection caused by the Beijing 02-171 Mtb strain. Our 
data does not support the previously suggested observation that BCG does not afford protection 
against infection with Mtb strains from the Beijing lineage [19, 21]. 
 
 
 
Figure 11 – BCG immunization induces protective immunity against a Beijing TLR4-activating Mtb 
strain in WT mice. BCG vaccinated (02-171+BCG) (open circles, dashed line) or unvaccinated (02-171) (closed 
circles, solid line) WT mice were infected with Mtb strain 02-171 via the aerosol route with a low dose of infection. At 
the indicated time points after infection mice were sacrificed and the bacterial burden were determined after 21 days 
of incubation by plating serial dilutions of lung (A) and liver (B) homogenates. The initial infection dose into the lungs 
was Log10 (CFUs) 2.250±0.037 (Mean ± SEM for 5 animals). The data points represent the Mean ± SEM of five mice 
per group and the statistical significance was determined by Two-way ANOVA with Bonferroni post-test. Data are from 
one experiment. (*, p≤0.05; **, p≤0.01; ***, p≤0.001) 
 
2.2 BCG-induced protection associates with an anticipation of CD4+ T cell response 
in the lungs of WT mice 
To gain insight into the mechanisms underlying BCG protection against 02-171 infection and given 
that CD4+ T cell responses have been shown of utmost importance in the control of Mtb infection 
[5, 56], we next compared by flow cytometry the CD4+ T cell response in the lungs of vaccinated 
and unvaccinated WT mice after aerosol challenge with a low dose of 02-171 Mtb strain. We 
observed an anticipation in the accumulation of both frequency and number of CD4+ T cells, on 
day 14 post-infection in the lungs of vaccinated WT mice compared with unvaccinated WT mice 
(Figure 12A and B). This increment was lost at day 20 after infection, with CD4+ T cell numbers 
becoming similar in both groups of infected mice after 20 days of infection (Figure 12B). In 
unvaccinated WT mice the number of CD4+ T cells in the lungs remained relatively constant until 
day 20 post-infection from which began to rise, peaking at day 30 post-infection and decreasing 
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thereafter (Figure 12B). During primary infection, T cell responses arrive to the site of infection 
around day 20 post-infection (Figure 12B) when Mtb infection starts to be controlled (Figure 11A). 
These data suggest that the higher numbers of CD4+ T cells at day 14 post-infection in vaccinated 
compared to unvaccinated WT mice (Figure 12B) associates with the better control of 02-171 Mtb 
growth in BCG immunized mice (Figure 11A), as it has been reported for H37Rv infection [103].  
 
 
Figure 12 – Increased frequency and number of lung CD4+ T cells at day 14 of infection in BCG 
vaccinated WT mice. BCG vaccinated (02-171+BCG) (open circles, dashed line) or unvaccinated (02-171) (closed 
circles, solid line) WT mice were infected with Mtb strain 02-171 via the aerosol route with a low dose of infection (Log10 
(CFUs) 2.250 ± 0.037 (Mean ± SEM for 5 animals). Infected mice were euthanized at the indicated time points after 
infection. Lung cell suspensions were prepared and the CD4+ T cells were analyzed by flow cytometry. (A) 
Representative FACS profile showing CD4 expression by lung cells at day 14 post-infection. The Mean ± SEM of CD4 
positive cells of each experimental group is indicated. (B) Percentage and total number of CD4 positive cells in the 
lung. The data points represent the Mean ± SEM of five mice per group and the statistical significance was determined 
by Two-way ANOVA with Bonferroni post-test. Data are from one experiment. (*, p≤0.05; **, p≤0.01; ***, p≤0.001) 
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2.3 BCG-mediated control of 02-171 Mtb infection associates with an early 
accumulation of IFN-+TNF+IL-2+ multifunctional CD4+ T cell response in the lungs 
of WT mice 
In order to characterize the phenotype of CD4+ T cell responses developed in BCG vaccinated 02-
171 infected mice, we compared by flow cytometry the ability of CD4+ T cells to produce IFN- in 
the lungs of vaccinated and unvaccinated WT mice after aerosol challenge with 02-171 Mtb strain. 
BCG vaccinated WT mice exhibited a higher frequency of lung IFN--producing CD4+ T cells at day 
14 after infection compared with WT 02-171-infected mice (Figure 13A and B). Although without 
statistical significance, we found the same tendency at this time point for the number of IFN--
producing CD4+ T cells (Figure 13B). In WT vaccinated mice, both frequency and number of IFN- CD4+ T cells, was already increased at day 14 of infection, raised from day 20 after infection, 
peaked at day 30 and then decreased becoming similar to WT unvaccinated mice (Figure 13B). In 
unvaccinated WT mice, the accumulation of IFN--producing CD4+ T cells in the lungs happened 
later on, with IFN--producing CD4+ T cells increasing from day 20 after infection, peaking at day 
30 post-infection and at day 90 the IFN--producing CD4+ T cells are already decreased (Figure 
13B). Therefore, the early IFN- response induced by BCG vaccination associates with the early 
Mtb growth arrest in WT BCG vaccinated mice (Figures 11A and 13B). Furthermore, at day 30 of 
Mtb infection, unvaccinated WT mice exhibited a higher frequency and number of IFN--producing 
CD4+ T cells than vaccinated WT mice, which again correlates with the control of Mtb infection in 
those mice (Figures 11A and 13B). However, at this time point the difference in IFN--producing 
CD4+ T cells in unvaccinated WT mice compared to vaccinated mice does not seem associate with 
an increased protection in the infected lungs of unvaccinated WT mice compared with vaccinated 
WT mice (Figures 11A and 13B). 
As previously mentioned, IFN- T cell responses play a critical protective role during Mtb infection 
[4, 5, 56, 86]. However the expression of this cytokine is not, by itself, sufficient to confer protection 
[130, 131]. It has been reported that the accumulation of multifunctional CD4+ T cells generated 
during vaccination that express IFN- in combination with TNF and IL-2 associate with increased 
protection against Mtb infection [130, 131]. Owing to the relevance of IFN--producing 
multifunctional CD4+ T cells in vaccine-induced protection, we analyzed by flow cytometry the co-
expression of IFN-, TNF and IL-2 by lung CD4+ T cells from 02-171 infected and BCG vaccinated 
or unvaccinated mice. The frequency of IFN-+TNF+IL-2+ CD4+ T cells was significantly higher in 
unvaccinated WT mice at day 14 post-infection, compared with vaccinated ones (Figure 13C and 
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D). After this time point the frequency of those CD4+ T cells dropped until day 20 after infection, 
becoming similar in both vaccinated and unvaccinated WT mice (Figure 13D). WT BCG vaccinated 
mice showed an increased number of lung CD4+ T cells co-producing IFN-, TNF and IL-2 at day 
14 post-infection compared with unvaccinated WT mice (Figure 13D). After this time point the 
number of this multifunctional CD4+ T cell population dropped until day 20 after infection, 
becoming similar to WT unvaccinated mice (Figure 13D). IFN-+TNF+IL-2+ T cells peaked at day 
30 post-infection, decreasing thereafter, in both groups of WT mice (Figure 13D). In accordance 
with the IFN- CD4+ T cell response, we also observed an early induction and accumulation of IFN-+TNF+IL-2+ multifunctional CD4+ T cells in vaccinated mice that might account for the better 
control of 02-171 Mtb infection in these mice. 
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Figure 13 – BCG vaccination leads to an early accumulation of lung IFN-+TNF+IL-2+ multifunctional 
CD4+ T cells after Mtb infection. BCG vaccinated (02-171+BCG) (open circles, dashed line) or unvaccinated (02-
171) (closed circles, solid line) WT mice were infected with Mtb strain 02-171 via the aerosol route with a low dose of 
infection (Log10 (CFUs) 2.250 ± 0.037 (Mean ± SEM for 5 animals). Infected mice were euthanized at the indicated 
time points after infection. Lung cell suspensions were prepared and cytokine production were analyzed by flow 
cytometry. (A) Representative FACS profile showing IFN- expression by lung CD4+ T cells at day 14 post-infection. 
The Mean ± SEM of IFN- positive cells of each experimental group is indicated. (B) Percentage and total number of 
IFN- positive cells on gated CD4+ T cells. (C) Representative FACS profile showing the expression of IL-2+ among 
IFN-+TNF+ by lung CD4+ T cells at day 14 post-infection. The Mean ± SEM of IFN-+TNF+IL-2+ cells of each 
experimental group is indicated. (D) Percentage and total number of IFN-+TNF+IL-2+ on gated CD4+ T cells. The 
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data points represent the Mean ± SEM of five mice per group and the statistical significance was determined by Two-
way ANOVA with Bonferroni post-test. Data are from one experiment. (**, p≤0.01; ***, p≤0.001) 
 
2.4 BCG-mediated control of 02-171 Mtb infection associates with an increased 
induction of IL-17+TNF+IL-2+ multifunctional CD4+ T cell responses in the lungs of 
WT mice 
It has been previously described that Th17 cells are important for BCG-induced protection by 
recruiting protective IFN--producing CD4+ T cells to the lungs [103]. Based on that, we next 
investigated, by flow cytometry, the kinetics of IL-17-producing CD4+ T cells in the lungs of 
vaccinated and unvaccinated WT mice after 02-171 aerosol challenge.  
Upon aerosol infection with 02-171 Mtb strain, we observed an increased frequency and number 
of IL-17+ CD4+ T cells in the lungs of BCG vaccinated, WT mice but not in unvaccinated, WT mice 
(Figure 14A). The increased numbers of IL-17-producing CD4+ T cells in vaccinated mice was 
observed for all the time points of our experiment, reaching the peak at day 30 after infection 
(Figure 14A). Of note, lung IL-17-producing CD4+ T cells did not coexpress IFN- (data not shown).  
Our group has recently described a novel multifunctional CD4+ T cell population co-expressing IL-
17, TNF and IL-2 that is associated with BCG-induced protection for infection with H37Rv (A. Cruz 
et al., submitted for publication). Given that, we next analyzed by flow cytometry this multifunctional 
CD4+ T cell population in the lungs of both groups of 02-171 aerosol infected WT mice. The 
frequency of lung IL-17+TNF+IL-2+ CD4+ T cells at day 14 post-infection was equal in both 
vaccinated and unvaccinated mice (Figure 14B). Then, in WT unvaccinated mice the frequency 
decreased until day 20 post-infection being significantly different from vaccinated mice, which 
showed a higher frequency (Figure 14B). From here on, the frequency of lung IL-17+TNF+IL-2+ 
CD4+ T cells were similar in both groups of mice (Figure 14B).  
The number of lung IL-17+TNF+IL-2+ CD4+ T cells was significantly higher at the days 14 and 30 
post-infection in BCG vaccinated mice than in unvaccinated-ones (Figure 14B). Although without 
statistical significance, in the remaining time points we observed the same tendency (Figure 14B). 
IL-17 induces the production of several proinflammatory cytokines, among which of GM-CSF [80, 
91]. So, we investigated the expression of GM-CSF in the CD4+ T cell population, by flow cytometry. 
In line with the increased expression of IL-17-producing CD4+ T cells, we observed that BCG 
vaccinated WT mice had an overall higher frequency and number of lung GM-CSF-producing CD4+ 
T cells compared to unvaccinated WT mice (Figure 14C). BCG vaccinated WT mice had a significant 
increased frequency of GM-CSF-producing CD4+ T cells for all time points tested (Figure 14C). In 
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both vaccinated and unvaccinated WT mice the frequency and number of lung GM-CSF-producing 
CD4+ T cells increased from the day 20 after infection, peaked at day 30 of infection, decreasing 
thereafter (Figure 14C). Despite the same tendency the number of GM-CSF-producing CD4+ T cells 
at days 20 and 30 after infection in vaccinated WT mice were not significantly different from those 
obtained for WT unvaccinated mice (Figure 14C).  
We concluded that upon aerosol infection with 02-171 Mtb strain, BCG vaccination can induce a 
higher expression of IL-17- and GM-CSF- producing CD4+ T cells that associate with the vaccine-
induced antimycobacterial function (Figures 11A, 14A and 14C). Furthermore, the novel IL-
17+TNF+IL-2+ multifunctional subset of  CD4+ T cells also associates with BCG-induced control of 
02-171 Mtb infection in WT mice (Figures 11A and 14B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – BCG vaccination leads to an early accumulation of lung IL-17, GM-CSF and IL-17+TNF+IL-
2+ multifunctional CD4+ T cells after Mtb infection. BCG vaccinated (02-171+BCG) (open circles, dashed 
line) or unvaccinated (02-171) (closed circles, solid line) WT mice were infected with Mtb strain 02-171 via the aerosol 
route with a low dose of infection (Log10 (CFUs) 2.250 ± 0.037 (Mean ± SEM for 5 animals). Infected mice were 
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euthanized at the indicated time points after infection. Lung cell suspensions were prepared and cytokine production 
were analyzed by flow cytometry. (A) Representative FACS profile showing IL-17 expression by lung CD4+ T cells at 
day 20 post-infection. The Mean ± SEM of IL-17 positive cells of each experimental group is indicated (left panel). 
Percentage and total number of IL-17 positive cells on gated CD4+ T cells (middle and right panels). (B) Representative 
FACS profile showing the expression IL-2+ among IL-17+TNF+ by lung CD4+ T cells at day 20 post-infection. The Mean 
± SEM of IL-17+TNF+IL-2+ cells of each experimental group was indicated (left panel). Percentage and total number 
of IL-17+TNF+IL-2+ cells on gated CD4+ T cells (middle and right panels). (C) Representative FACS profile showing 
GM-CSF expression by lung CD4+ T cells at day 20 post-infection. The Mean ± SEM of GM-CSF positive cells of each 
experimental group is indicated (left panel). Percentage and total number of GM-CSF positive cells on gated CD4+ T 
cells (middle and right panels). The data points represent the Mean ± SEM of five mice per group and the statistical 
significance was determined by Two-way ANOVA with Bonferroni post-test. Data are from one experiment. (*, p≤0.05; 
**, p≤0.01; ***, p≤0.001) 
 
2.5 BCG vaccination prevents severe lung inflammation induced by 02-171 Mtb 
infection in WT mice 
A hallmark of Mtb infection is the granuloma formation, which has an essential function in host 
protection against the infection [132]. IL-17 is induced upon Mtb infection and contributes to 
several steps of the immune response, particularly for the infection-induced granuloma formation 
[132]. Moreover, IL-17 also impacts neutrophil recruitment which is often associated with lung 
inflammation [80]. Given that we found a higher expression of this cytokine in BCG WT vaccinated 
mice (Figure 14A), we next investigated the influence of BCG vaccination on the development of 
lung inflammation upon infection with 02-171 Mtb strain. For that, we stained with H&E the upper 
right lobe of the lungs of BCG vaccinated and unvaccinated aerosol 02-171 infected WT mice. The 
lungs of both groups of WT 02-171-infected mice developed progressive lung lesions after day 20 
post-infection (Figure 15). Mice that were vaccinated with BCG showed reduced lung inflammation 
at days 30 and 90 post-infection compared with unvaccinated WT mice (Figure 15). At day 90 post-
infection in unvaccinated WT mice, a vast proportion of the lung tissue was occupied with 
inflammatory infiltrates (Figure 15). As expected, uninfected vaccinated and unvaccinated WT mice 
did not exhibited lung inflammation (Figure 15). 
Although we observed a higher induction of IL-17 production by lung CD4+ T cells in BCG WT 
vaccinated mice (Figure 14A), this increased expression did not cause lung tissue damage (Figure 
15). 
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Overall, in WT vaccinated mice the inflammatory infiltrates were smaller, less extensive and 
appeared more organized than those exhibited by unvaccinated WT mice (Figure 15), indicating 
that BCG-induced immunity controls immunopathology after infection with 02-171 Mtb strain. 
 
 
 
Figure 15 – Reduced lung inflammation in WT BCG vaccinated mice following aerosol infection with 
02-171 Mtb strain. BCG vaccinated (02-171+BCG) or unvaccinated (02-171) WT mice were infected with Mtb strain 
02-171 via the aerosol route with a low dose of infection (Log10 (CFUs) 2.250 ± 0.037 (Mean ± SEM for 5 animals). 
To assess lung inflammation upper right lobes of the lung were excised from WT unvaccinated (top panel) or WT 
vaccinated (bottom panel) mice and fixed lung sections were stained with H&E. Representative images from each 
experimental group were obtained. Images represented for day 0 correspond to uninfected animals. Data are from one 
experiment. 
 
2.6 BCG vaccination protects TLR4 -/- mice against infection by the Beijing TLR4-
activating Mtb strain 02-171 
Our data add to the controversy regarding the protection conferred by BCG against Mtb strains of 
the Beijing lineage. Indeed, we clearly show that not only BCG protects mice from infection with 
02-171, but also the mechanisms underlying such protection are similar to those in place using 
Mtb H37Rv, the laboratory reference strain of the Euro-American lineage.  
We have recently shown that Mtb strain 02-171 triggers TLR4 in addition to TLR2 [34]. Furthermore, 
TLR4 agonists have been used as adjuvants in human and also in experimental vaccines, to boost 
T cell-mediated immune responses [118, 120-122]. Thus, we next investigated the role of TLR4 
signaling in the protection conferred by BCG vaccination against 02-171 Mtb infection. For that, 
TLR4 -/- mice were vaccinated or not with BCG and, 90 days later, infected via the aerosol route 
with 02-171 Mtb strain.  
To assess the effectiveness of BCG vaccination in TLR4 -/- mice, we evaluated the mycobacterial 
growth in relevant organs namely in the lungs, the primary site of infection, and in the liver, that 
63 
 
represents the dissemination of Mtb. We observed that BCG vaccination, prior to 02-171 infection 
of TLR4 -/- mice, controlled the bacterial growth in the lungs and in the liver as soon as 14 days 
post-infection (Figure 16A and B). Indeed, in the lung, BCG vaccination arrested Mtb growth from 
day 14 up to day 90 of infection (Figure 16A). This strongly suggests that the protection conferred 
by BCG against Mtb 02-171 infection is long lasting.  
In the liver, although we observed a significant protection at day 14 post-infection, there was Mtb 
growth until day 20 of infection after which time point the bacterial load decreased and stabilized 
(Figure 16B). These findings indicate that activation of TLR4 by Mtb strain 02-171 does not impact 
the efficacy of BCG vaccination.  
 
 
 
Figure 16 – TLR4 absence does not influence the effectiveness of BCG vaccination in protecting mice 
against a Beijing TLR4-activating Mtb strain infection. BCG vaccinated (02-171+BCG) (closed squares, dashed 
line) or unvaccinated (02-171) (open squares, solid line) TLR4 -/- mice were infected with Mtb strain 02-171 via the 
aerosol route with a low dose of infection. At the indicated time points after infection mice were sacrificed and the 
bacterial burden determined after 21 days of incubation by plating serial dilutions of lung (A) and liver (B) 
homogenates. The initial infection dose into the lungs was Log10 (CFUs) 2.229±0.056 (Mean ± SEM for 2 animals). 
The data points represent the Mean ± SEM of at least 4 mice per group and the statistical significance was determined 
by Two-way ANOVA with Bonferroni post-test. Data are from one experiment. (*, p≤0.05; **, p≤0.01; ***, p≤0.001) 
 
2.7 BCG-induced protection associates with an anticipation of CD4+ T cell response 
in the lungs of TLR4 -/- mice 
We next compared by flow cytometry the CD4+ T cell response in the lungs of vaccinated and 
unvaccinated TLR4 -/- mice after aerosol challenge with 02-171 Mtb strain. We found that at day 
14 of Mtb infection the frequency of lung CD4+ T cells was similar in both vaccinated and 
unvaccinated TLR4 -/- mice (Figure 17B). Then, the CD4+ T cells in TLR4 -/- vaccinated mice 
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increased, peaking at day 20 and decreasing afterwards, while in TLR4 -/- unvaccinated mice the 
maximum percentage of CD4+ T cells was achieved later, at day 30 post-infection (Figures 17A 
and B). The same trend was observed in terms of CD4+ T cell numbers in the lungs of infected 
mice (Figure 17B). In all, we observed an anticipation of the peak of CD4+ T cells, which most 
likely accounts for the early Mtb growth arrest, in TLR4 -/- vaccinated mice (Figure 16A and 17B). 
 
 
 
Figure 17 – BCG-induced protection associates with an increased frequency of lung CD4+ T cell 
response at day 20 of infection in TLR4-/- mice. BCG vaccinated (02-171+BCG) (closed squares, dashed line) 
or unvaccinated (02-171) (open squares, solid line) TLR4 -/- mice were infected with Mtb strain 02-171 via the aerosol 
route with a low dose of infection (Log10 (CFUs) 2.229 ± 0.056 (Mean ± SEM for 2 animals). Infected mice were 
euthanized at the indicated time points after infection. Lung cell suspensions were prepared and the CD4+ T cells 
were analyzed by flow cytometry. (A) Representative FACS profile showing CD4 expression by lung cells at day 20 
post-infection. The Mean ± SEM of CD4 positive cells of each experimental group is indicated. (B) Percentage and 
total number of CD4 positive cells in the lung. The data points represent the Mean ± SEM of at least four mice per 
group and the statistical significance was determined by Two-way ANOVA with Bonferroni post-test. Data are 
representative of one experiment. (*, p≤0.05; **, p≤0.01) 
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2.8 BCG-mediated control of 02-171 Mtb infection associates with an early 
accumulation of IFN- and IFN-+TNF+IL-2+ multifunctional CD4+ T cell response in 
the lungs of TLR4 -/- mice 
We next compared by flow cytometry the IFN- T cell response in the lungs of vaccinated and 
unvaccinated TLR4 -/- mice after aerosol challenge with 02-171 Mtb strain. TLR4 -/- BCG 
vaccinated mice exhibited a higher frequency of IFN--producing CD4+ T cells in the lungs on days 
14 and 20 after infection compared with TLR4 -/- unvaccinated 02-171-infected mice (Figures 18A 
and B). Moreover, in TLR4 -/- vaccinated mice we observed an anticipation in the peak of lung IFN--producing CD4+ T cells to day 20 post-infection versus day 30 in unvaccinated mice (Figure 
18B). The frequency of this population was similar in both vaccinated and unvaccinated TLR4 -/- 
mice at days 30 and 90 after Mtb infection (Figure 18B). The same trend was observed for the 
number of IFN- CD4+ T cells (Figure 18B).  
Owing to the relevance of IFN--producing multifunctional CD4+ T cells in vaccine-induced 
protection [130, 131], we next analyzed whether TLR4 signaling during Mtb infection altered the 
co-expression of IFN-, TNF and IL-2 in lung CD4+ T cells by flow cytometry. The frequency of lung 
IFN-+TNF+IL-2+ CD4+ T cells decreased over the time and curiously we observed an increased 
frequency of this multifunctional CD4+ T cell population in unvaccinated TLR4 -/- mice at day 20 
after Mtb infection compared with TLR4 -/- vaccinated mice (Figures 18C and D). The number of 
lung IFN-+TNF+IL-2+ CD4+ T cells in TLR4 -/- vaccinated mice peaked earlier and was 
significantly higher than that observed in unvaccinated TLR4 -/- mice (Figure 18D). After day 20 of 
infection the number of this multifunctional CD4+ T cell population in vaccinated mice dropped, 
becoming similar what was observed for unvaccinated mice (Figure 18D). In accordance with the 
dynamics observed for the IFN- T cell response, we also observed an early induction and 
accumulation of this multifunctional T cell population in vaccinated mice (Figure 18D) that might 
account for the better control of 02-171 Mtb infection in TLR4 -/- BCG vaccinated mice compared 
with TLR4 -/- unvaccinated-ones.  
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Figure 18 – BCG vaccination leads to an early accumulation of lung IFN-+TNF+IL-2+ multifunctional 
CD4+ T cells in the lungs of TLR4-/- mice. BCG vaccinated (02-171+BCG) (closed squares, dashed line) or 
unvaccinated (02-171) (open squares, solid line) TLR4-/- mice were infected with Mtb strain 02-171 via the aerosol 
route with a low dose of infection (Log10 (CFUs) 2.229 ± 0.056 (Mean ± SEM for 2 animals). Infected mice were 
euthanized at the indicated time points after infection. Lung cell suspensions were prepared and cytokine production 
was analyzed by flow cytometry. (A) Representative FACS profile showing IFN- expression by lung CD4+ T cells at 
day 20 post-infection. The Mean ± SEM of IFN- positive cells of each experimental group is indicated. (B) Percentage 
and total number of IFN- positive cells on gated CD4+ T cells. (C) Representative FACS profile showing the expression 
of IL-2+ among IFN-+TNF+ by lung CD4+ T cells at day 20 post-infection. The Mean ± SEM of IFN-+TNF+IL-2+ cells 
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of each experimental group is indicated. (D) Percentage and total number of IFN-+TNF+IL-2+ on gated CD4+ T cells. 
The data points represent the Mean ± SEM of at least four mice per group and the statistical significance was 
determined by Two-way ANOVA with Bonferroni post-test. Data are from one experiment. (*, p≤0.05; **, p≤0.01; ***, 
p≤0.001) 
 
2.9 BCG-mediated control of 02-171 Mtb infection associates with an increased 
induction of GM-CSF but not IL-17 or IL-17+TNF+IL-2+ CD4+ T cell responses in the 
lungs of TLR4 -/- mice 
We next investigated by flow cytometry the IL-17 CD4+ T cell response in the lungs of vaccinated 
and unvaccinated TLR4 -/- mice after 02-171 aerosol challenge. In contrast to what we observed 
for WT BCG vaccinated mice (Figure 14A), we found that BCG immunization did not induce a higher 
frequency and number of IL-17-producing CD4+ T cells in the lungs of TLR4 -/- mice (Figure 19A). 
At days 14, 20 and 90 after Mtb infection the number of IL-17-producing CD4+ T cells was indeed 
similar among vaccinated and unvaccinated TLR4 -/- mice (Figure 19A). In TLR4 -/- BCG 
vaccinated mice the maximum number of IL-17 CD4+ T cells occurred on day 20 after infection, 
whereas for TLR4 -/- unvaccinated animals the number of IL-17-producing CD4+ T cells continued 
to increase until day 30 of infection, dropping afterwards (Figure 19A). The frequency of those cells 
were identical for both groups of TLR4 -/- mice for all the time points tested (Figure 19A). 
We next analyzed by flow cytometry the co-expression of IL-17, TNF and IL-2 by CD4+ T cell 
population in the lungs of vaccinated and unvaccinated TLR4 -/- 02-171-infected mice. The 
frequency of lung IL-17+TNF+IL-2+ CD4+ T cells was similar for both groups of mice at day 14 of 
infection (Figure 19B). In TLR4 -/- unvaccinated mice, the frequency of this multifunctional CD4+ 
T cell population increased until day 20 post-infection and stabilized afterwards, being significantly 
higher than in vaccinated mice at the days 20, 30 and 90 post-infection (Figure 19B). In what 
concerns cell numbers, this T cell population peaked in TLR4 -/- unvaccinated mice at day 30 of 
infection (Figure 19B). Only at this time point was the number of IL-17+TNF+IL-2+ CD4+ T cells 
significantly higher than in TLR4 -/- vaccinated animals (Figure 19B). In fact, in vaccinated TLR4 -
/- mice the number of IL-17+TNF+IL-2+ CD4+ T cells remained relatively stable for all time points 
tested (Figure 19B). Overall, our data suggest that TLR4 triggering is important for the induction of 
IL-17-producing CD4+ T cells during BCG vaccination. However, whether this signal is required 
during vaccination, infection or both, remains to be elucidated.  
Finally, we analyzed the production of GM-CSF among the CD4+ T cell population. BCG vaccinated 
TLR4 -/- mice showed a significantly higher frequency and number of lung GM-CSF-producing 
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CD4+ T cells than unvaccinated mice at day 20 post-infection (Figure 19C). Although not 
statistically different, at day 14 of infection the same trend was observed (Figure 19C). For BCG 
vaccinated TLR4 -/- mice, the frequency and number of GM-CSF-producing CD4+ T cells peaked 
at day 20 of infection, decreasing thereafter (Figure 19C). This represented an anticipation of this 
T cell population, as for unvaccinated TLR4 -/- mice, the peak of GM-CSF-producing CD4+ T cells 
happened on day 30 post-infection (Figure 19C). Additionally, we observed that for TLR4 -/- mice 
the increased production of GM-CSF by CD4+ T cells was not associated with an increased IL-17 
CD4+ T cell response (Figures 19A and C) as we hypothesized for WT mice. 
As for WT mice, the data suggest that BCG vaccination can induce an early expression of GM-CSF-
producing CD4+ T cells upon aerosol infection with 02-171 Mtb strain that might associate with 
the vaccine-induced antimycobacterial function. The differentiation of these cells appears therefore 
to be independent of TLR4.  
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Figure 19 – BCG vaccination leads to an early accumulation of lung GM-CSF but not IL-17 and IL-
17+TNF+IL-2+ multifunctional CD4+ T cells after Mtb infection of TLR4 -/- mice. BCG vaccinated (02-
171+BCG) (closed squares, dashed line) or unvaccinated (02-171) (open squares, solid line) TLR4-/- mice were 
infected with Mtb strain 02-171 via the aerosol route with a low dose of infection (Log10 (CFUs) 2.229 ± 0.056 (Mean 
± SEM for 2 animals).  Infected mice were euthanized at the indicated time points after infection. Lung cell suspensions 
were prepared and cytokine production was analyzed by flow cytometry. (A) Representative FACS profile showing IL-
17 expression by lung CD4+ T cells at day 20 post-infection. The Mean ± SEM of IL-17 positive cells of each 
experimental group is indicated (left panel). Percentage and total number of IL-17 positive cells on gated CD4+ T cells 
(middle and right panels). (B) Representative FACS profile showing the expression of IL-2+ among IL-17+TNF+ by lung 
CD4+ T cells at day 20 post-infection. The Mean ± SEM of IL-17+TNF+IL-2+ positive cells of each experimental group 
is indicated (left panel). Percentage and total number of IL-17+TNF+IL-2+ positive cells on gated CD4+ T cells (middle 
and right panels). (C) Representative FACS profile showing GM-CSF expression by lung CD4+ T cells at day 20 post-
infection. The Mean ± SEM of GM-CSF positive cells of each experimental group is indicated (left panel). Percentage 
and total number of GM-CSF positive cells on gated CD4+ T cells (middle and right panels). The data points represent 
the Mean ± SEM of at least four mice per group and the statistical significance was determined by Two-way ANOVA 
with Bonferroni post-test. Data are from one experiment. (*, p≤0.05; **, p≤0.01; ***, p≤0.001) 
 
2.10 BCG immunization reduces immunopathology after 02-171 Mtb infection in 
TLR4 -/- mice 
We next evaluated the lung inflammation after 02-171 Mtb infection of BCG vaccinated and 
unvaccinated TLR4 -/- mice. For that, we stained with H&E the upper right lobe of the lungs of both 
groups of TLR4 -/- mice. The lungs of both, vaccinated and unvaccinated, TLR4 -/- 02-171-infected 
mice exhibited progressive lung lesions after day 20 post-infection (Figure 20). Mice that were 
vaccinated with BCG showed reduced lung inflammation at days 30 and 90 post-infection 
compared with unvaccinated TLR4 -/- mice (Figure 20). Overall, we observed a slower progression 
of lung inflammation in BCG vaccinated TLR4 -/- mice compared to unvaccinated mice (Figure 20). 
Furthermore, it seems that at day 90 of Mtb infection both vaccinated and unvaccinated TLR4 -/- 
mice had a reduced lung inflammation compared with the respective groups of WT animals (Figures 
15 and 20).  
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Figure 20 – BCG immunization reduces lung inflammation in TLR4 -/- mice infected with 02-171 Mtb 
strain. BCG vaccinated (02-171+BCG) or unvaccinated (02-171) TLR4 -/- mice were infected with Mtb strain 02-171 
via the aerosol route with a low dose of infection (Log10 (CFUs) 2.229 ± 0.056 (Mean ± SEM for 2 animals). To assess 
lung inflammation upper right lobes of the lung were excised from TLR4 -/- unvaccinated (top panel) or TLR4 -/- 
vaccinated (bottom panel) mice and fixed lung sections were stained with H&E. Representative images from each 
experimental group were obtained. Images represented for day 0 correspond to uninfected animals. Data are from one 
experiment. 
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TB still represents a severe public health problem [1]. Although anti-TB drugs are available for 
decades, Mtb still causes the death of nearly two million people annually [1]. Currently, the co-
infection with HIV and the emergence of MDR strains, related to noncompliance or to an 
inappropriate drug regimen, have further complicated the TB control [1, 2]. BCG vaccination has 
demonstrated its efficacy in preventing childhood TB, but the limited and variable protection against 
adulthood TB leaves this serious public health problem without a widely efficacious vaccine [101, 
102, 133].  
One of the most intriguing issues in TB is the large spectrum of TB outcomes, which can range 
from clearance, to latent infection to active disease affecting multiple organs – miliary TB [7]. In 
response to Mtb infection, the immune response is activated, but such activation needs to be 
cautiously balanced [56, 99]. On one hand, the immune response has to be strong enough to fight 
the infection. On the other hand, it needs to be controlled in order to prevent extensive tissue 
damage [56, 99]. However, in most of cases of Mtb infection, the immune response generated by 
the host is not efficient enough to clear the pathogen, but instead it leads to an inactivated form of 
the disease [56, 99]. When the fine balance established during latency is broken, Mtb infection 
rapidly reactivates, which happens in 5 to 10% of Mtb cases, and progresses to active disease [6, 
56, 99].  
Both host and pathogen features can contribute to the development of active TB [6, 7, 15]. Among 
them, the pathogen strain variability, which could account for differences in the virulence [12, 21]. 
The human genetic background, singular polymorphisms, life habits and comorbidities could also 
associate with increased TB susceptibility [15, 43, 86]. 
Studies in animals models using clinical isolates showed the complexity and heterogeneity of the 
immune response induced in the host [21, 134, 135]. These observations demonstrate some of 
the limitations in the exclusive use of laboratory strains, which can also oversimplify this complex 
disease. Therefore, the use of clinical isolates of Mtb could be one way to overcome this issue, 
given that they are likely less adapted to laboratory conditions, thus better reflecting the progress 
of Mtb strains during infection. Moreover, TB vaccines are normally tested against the laboratory 
strains and limited information is available to understand whether BCG vaccine will be effective 
against the newly emerging clinical strains of Mtb, as Beijing strains [20]. This is an important 
issue to take into account, because the wide diversity in the virulence and pathogenesis of Mtb 
strains could have a huge impact on the diagnosis, treatment response and also BCG efficacy 
[136].  
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The emergence and spread of new Mtb strains have raised considerable concern. Of particular 
significance is the Beijing family of strains that is believed to have increased pathogenicity, a 
propensity to evade the protection mediated by BCG and increased drug resistance [18, 19, 21].  
It has been described that human macrophages have a differential cytokine production after 
infection with different Mtb strains therefore showing a distinct interaction with innate immune cells 
and a heterogeneous response [135]. Our recent data showed that in a panel of Beijing strains, 
most of the strains were recognized by TLR2 in BMDM. However, 02-171 Mtb strain was also 
recognized by TLR4 [34]. Therefore, we suggest that differential TLR recognition of Mtb strains may 
be one of the host molecular basis underlying heterogeneous immune responses to Mtb. 
 
In the Chapter I of this thesis we investigated the role of TLR4 activation on T cell development 
during primary infection with 02-171, a Beijing TLR4-activating Mtb strain. For that, we infected 
WT and TLR4 -/- mice via the aerosol route with a low dose of 02-171 Mtb strain. 
At day 25 post primary infection with 02-171 Mtb strain, we observed that TLR4 triggering 
increased the frequency of CD4+ T cells. However, when we looked to the total number of CD4+ 
T cells no difference was found. The total number of lung cells in both groups of mice was similar 
at this time point (data not shown). The number of CD4+ T cells in WT and TLR4 -/- animals, did 
not reach significance may be due to some heterogeneity within the groups. 
We hypothesized that the increment in the frequency of CD4+ T cell can be explained by differential 
local proliferation in the infected lungs. To test our hypothesis, 24 hours before the experimental 
time point, both strains of 02-171-infected mice were intraperitoneally injected with BrdU, and cells 
actively synthesizing DNA were detected by flow cytometry. We found that the increased frequency 
of CD4+ T cells in WT mice was independent of local proliferation. Therefore, it most likely is a 
consequence of enhanced cell recruitment to the lungs. In support of this hypothesis is the finding 
that the expression of Cxcl10 and Cxcl11, chemokines involved in the recruitment of T cells, was 
increased in WT mice as compared to TLR4 -/- at day 20 post-infection. Other hypotheses that 
could explained the difference observed are the increased survival in the lungs or the earlier priming  
in the LN of CD4+ T cells in infected WT mice compared with TLR4 -/-. These hypotheses need 
further clarification and are the scope of ongoing studies.  
Furthermore, TLR4 activation seems not to influence the phenotype of CD4+ T cells at least for the 
activation markers tested. 
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We next investigated the impact of TLR4 activation during 02-171 Mtb infection on the lung IFN- 
response. We found that TLR4 triggering did not impact lung IFN- production by CD4+ T cells. 
However, when we looked for Ifng expression in the total lung we observed that at day 32 of 
infection TLR4 -/- mice showed significant higher levels of this cytokine when compared to WT 
animals. CD4+ T cells are the primary source of IFN- during the adaptive immune response to Mtb 
infection [56]. However, other cell types such as CD8+ T cells, NK cells and NKT cells can also 
produce IFN- upon Mtb challenge [56, 137]. It is therefore possible that these other cell 
populations contribute for the higher IFN- expression in the infected lungs of TLR4 -/- mice, but 
such hypothesis needs further confirmation. Furthermore, the increased IFN- production in TLR4 
-/- does not associate with a better control of Mtb infection, further supporting the idea that IFN-, 
by itself, is not sufficient to induce Mtb growth arrest [108].  
Additionally, we have to keep in mind that the production of cytokines by CD4+ T cells was assessed 
after ex vivo re-stimulation using PMA and ionomycin together with brefeldin A. This method will 
lead to the activation of several intracellular signaling pathways that allows us to identify what is 
the cytokine profile of CD4+ T cells in the infected lungs [138]. Ex vivo re-stimulation reveals a 
specific phenotype that T cells have acquired during infection, but that may not necessarily be 
“active” at the site of infection.  
We next investigated the kinetics of lung IL-17-producing CD4+ T cells by flow cytometry. We 
observed that the frequency of IL-17-producing CD4+ T cells was enhanced in TLR4 -/- mice as 
compared to WT 02-171-infected animals. Indeed, the dynamics of IL-17 CD4+ T cell response in 
TLR4 -/- seemed anticipated as compared with WT mice. Nevertheless, the difference observed for 
IL-17 CD4+ T cells did not impact the control of 02-171 Mtb infection, with the TLR4 -/- mice being 
as resistant as WT-infected mice. Indeed, it has been reported that IL-17 does not play a major 
protective role in primary Mtb infection, being mainly involved in the maintenance of the 
inflammatory response [139, 140]. 
When we investigated the relative mRNA expression of Il-17 in the total lung we did not observe 
significant differences among WT and TLR4 -/- mice. Thus, it is possible that in the total lung the 
contribution of other cell types is masking the differences observed in CD4+ T cells. Indeed, it has 
been described that upon Mtb infection,  T cells rather than CD4+ T cells are an important 
source of IL-17 [69]. In a future approach, we will include in our FACS staining a specific marker 
to evaluate the production of IL-17 by  T cells. In addition, we could also perform an enrichment 
of lung CD4+ T cells by positive selection to evaluate the Il-17 mRNA expression. Moreover, we 
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could re-stimulate lung cells with PMA plus ionomycin without brefeldin A to measure the IL-17 
protein in the lung supernatant by ELISA. One another hand, it is possible that the higher production 
of IL-17 by lung CD4+ T cells was not reflected at the mRNA expression level.  
On possible explanation for the increased production of IL-17 in TLR4 -/- infected mice compared 
to WT mice is that TLR4 in addition to MyD88 also trigger an alternative signaling pathway via TRIF 
adaptor molecule, that allow the induction of a different profile of the immune response, specifically 
the type I IFN production [23, 24]. Type I IFN has been shown to negatively impact the generation 
of Th17 cells, by inducing IL-27 production, which has been reported as a negative regulator of IL-
17 secretion [141]. However, this is a conflicting issue because other reports state that TLR4 and 
dectin1 receptors are responsible for Mtb-induced IL-17 responses [140]. Accordingly to the last 
work we expected to find lower IL-17 production in TLR4 -/- than in WT mice. However, this was 
not the case, therefore it is probable that dectin1 and possible other PRRs compensate for the IL-
17 production. Therefore, in the future it will be interesting understand which are the molecular 
mechanisms responsible for IL-17 inducing upon Mtb infection and the possible cross-talk between 
PRRs.  
Given the role of IL-17 in the maintenance of the inflammatory response after Mtb infection [139], 
and despite the differences observed in the IL-17 response. We did not observe significant 
differences in the number of neutrophils neither in lung inflammation among WT and TLR4 -/- 
infected mice. We also concluded that TLR4 activation by 02-171 Mtb strain did not impact Nos2 
expression and NOS2 protein, since we observed similar levels in both groups of Mtb-infected mice. 
During Mtb infection, IFN- and TNF signaling synergize to the induction of NOS2 [5, 56]. Our 
previous work showed that the absence of TLR4 triggering in 02-171 intranasal infected mice 
decreased the cytokine expression, such as IFN- and TNF, which is accompanied by a decreased 
Nos2 expression with consequence lack of protection against 02-171 Mtb infection. In our work, 
we did not observe significantly differences in IFN- and TNF production, neither Nos2 expression 
in the presence or not of TLR4 triggering. Therefore, we hypothesized that the levels of IFN- and 
TNF can at least partially explain Nos2 expression. Reasons for our apparent contrasting data are 
discussed below. 
In accordance with what we observed for the IFN- response, lung pathology and NOS2 expression 
the progression of bacterial burden in the lungs and in the LN were similar for both strains of mice 
at all time points tested. It is still possible that TLR4 absence impacts the protection against Mtb 
in a chronic phase of the infection. Therefore in a future experiment we have to include later time 
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points as 90 or 150 days post-infection, as there is a precedent in the literature to support this 
hypothesis. It has been described that TLR2 -/- mice were more susceptible to Mtb infection than 
control animals [28]. In this reported work, the bacterial burden in the lungs was only measured 
at two time points, specifically at days 30 and 150 post-infection, and only in the latest time point, 
differences were observed for both experimental groups [28].  
Altogether our data suggest that TLR4 activation during a primary infection by a TLR4-activacting 
strain, at least in an aerosol standard infection dose and in the time points tested, may not play a 
significant role in the course of infection. These findings, are in apparent contrast with what we 
published before, which suggest a protective role for TLR4 triggering upon intranasal infection with 
02-171 Mtb strain [34]. These conflicting results, can be explained by the different route of infection 
(intranasal vs aerosol) and/or by the initial inoculum dose (low vs high dose). In what respects the 
route of infection, differences between the intranasal and aerosol models have not been explored 
yet. However, during an aerosol infection the bacteria is delivered to the lower respiratory tract, 
whereas after an intranasal infection, the bacteria contacts with the upper respiratory tract until it 
reaches the lower airways, thus interacting with different cells and possibly activating different 
pathways from both the upper and lower respiratory tract, which could influence the outcome of 
the Mtb infection. In support of the initial inoculum dose, it has been reported in the literature that, 
at low dose, TLR2 -/- are as resistant to infection as WT mice, however with a higher infection dose 
TLR2 -/- mice exhibited an increased susceptibility compared with control animals, suggesting that 
TLR2 triggering is needed for the protection to a higher Mtb challenge [33]. Moreover, in murine 
models of B cell deficiency and IL-17 deficiency showed that upon high, but not low inoculum dose 
of Mtb, mice were more susceptible to infection compared to control mice [72, 73, 80].  
Additionally, we have also data from our laboratory that demonstrate that a mild although significant 
difference in the inoculum size could alter the susceptibility of mice NOS2 -/- to Mtb infection.  
Thus, in the attempt to unmask the role of TLR4 triggering on the control of Mtb infection by a 
TLR4-activating Mtb strain not apparent in the standard aerosol experimental infection (around 100 
to 200 CFU), we are presently performing an experiment in which we elevated the initial infection 
dose of Mtb to approximately 500 CFUs. 
 
In the Chapter II of this thesis we explored the importance of the TLR4 triggering by 02-171 Mtb 
strain during a recall response after BCG vaccination. 
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Recently, it has been postulated that the BCG-induced protective immunity may be Mtb strain-
specific which may contribute to the limited efficacy of this vaccine [19]. The proposed model is 
consistent with the growing body of evidence on the genetic heterogeneity and phenotypic 
differences among Mtb strains [15, 129]. Therefore, differential host-pathogen interactions caused 
by phenotypic differences among Mtb strains could alter BCG-induced immunity, causing limited 
protective responses to specific Mtb strains [142]. 
Among the most prevalent of the Mtb genotypes are the Beijing strains which have been associated 
with worldwide TB outbreaks [17, 18]. It also been reported that, in mice, BCG vaccination showed 
less protection against challenge with a Beijing strain than against infection with the H37Rv strain 
[21]. These data are not definitive as another work reported that in the mouse model of pulmonary 
Mtb infection, BCG immunization protected equally well against infection with diverse Mtb strains, 
including strains of the Beijing genotype, thus suggesting that strain-specific resistance to BCG-
induced protective immunity may be unusual [115]. Thus, the association between Beijing strains 
and the efficacy of BCG vaccination is still unclear. Taking into account this problematic and our 
previous published work on the activation of TLR4 by particular Mtb strains [34], we hypothesized 
that the differential TLR recognition of Mtb strains could also account for the variability of BCG-
induced protection.  
Our findings showed that BCG vaccination is effective at controlling the infection caused by 02-171 
Mtb strain, suggesting that BCG immunization can be protective against an infection caused by a 
Beijing Mtb strain that activates TLR4. Our results, thus favor the hypothesis that not all Beijing 
strains are resistant to protection afforded by BCG. Thus, the idea that BCG vaccination does not 
protect against Beijing genotypes needs to be revisited. Only a limited number of comparative 
studies have been performed to examine post-vaccination protection induced by BCG against 
Beijing strains. Thus it will be interesting to extend our study to a larger panel of Mtb isolates from 
different lineages to advance our knowledge on whether BCG efficacy depends on the heterogeneity 
of Mtb strains and whether it associates with differential TLR recognition.  
Although BCG protected both WT and TLR4 -/- mice from 02-171 infection, some differences were 
observed, which may be of interest. Indeed, in vaccinated TLR4 -/- mice the bacterial burden was 
controlled from day 14 post-infection up to day 90. At day 14 post-infection, although protected, 
BCG vaccinated WT mice had not yet arrested Mtb growth, with the infection progressing at a 
slower rate until day 20. From this time point on, the protection was similar for both strains of 
immunized mice. It will now be interesting to understand why in WT vaccinated mice the Mtb 
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growth does not stop at day 14 post-infection as we observed for vaccinated TLR4 -/- mice. These 
results might suggest that in WT vaccinated mice the protective T cell response arrived early to the 
lungs although, was not sufficient to control the infection. In the liver, the TLR4 triggering did not 
impact the protection evoked by BCG.  
We next investigated the role of TLR4 triggering on the development of CD4+ T cell responses in 
BCG vaccinated mice. Overall, we observed that WT vaccinated mice compared to unvaccinated-
ones showed an earlier IFN- CD4+ T cell response that associates with Mtb infection control. 
Interestingly, in TLR4 -/- mice the highest levels of IFN- and multifunctional IFN-+TNF+IL-2+ T 
cells were achieved at day 20, while in TLR4 -/- unvaccinated mice and in both WT vaccinated and 
unvaccinated mice the same happens later on at day 30 post-infection. These data suggest that 
the dynamics of CD4+ T cells after BCG vaccination is different in WT and TLR4 -/- animals, but 
the mechanism underlying this difference remain elusive. 
It is becoming increasingly recognized that the quality of vaccine-induced T cell responses is crucial 
for developing effective immunization strategies [143]. It has been proposed that multifunctional T 
cells secreting multiple cytokines are able to proliferate upon encounter with antigen and are more 
likely than single cytokine producers to represent correlates of protective immunity in chronic 
infections [144]. The factors responsible for the better efficacy of multifunctional T cells are 
unknown but possibly include the ability of multifunctional T cells to secrete simultaneously high 
levels of cytokines. IFN- and TNF secretion could synergize for intracellular killing, and IL-2 act on 
promoting further T cell expansion [143]. 
In humans some reports have suggested that multifunctional Mtb-specific CD4+ T cells play an 
essential role in protective immunity against TB [145]. Additionally, mouse studies with 
leishmaniosis and TB vaccines have shown an association between vaccine-induced 
multifunctional T cells and vaccine-induced protective immunity against intracellular pathogens 
[108, 111, 130].  
However, another study reported that the frequency of multifunctional CD4+ T cells producing 
several cytokines (IFN-, TNF and IL-2) is significantly increased in individuals with active TB 
disease, not supporting the existing idea that such responses might be correlated with protection 
[114].  
In our studies, multifunctional T cells are also presented and seem to associate with vaccine-
induced protection, so their importance comes up as robust. Clearly, further characterization of 
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multifunctional T cell responses induced in both mice and humans is needed to assess whether 
these populations are actually conferring protection against Mtb infection. 
It has been shown that IL-17-producing cells mediate vaccine-induced protective immunity by 
promoting an earlier recruitment of IFN--producing cells to the Mtb-infected lungs [103]. 
In WT mice, BCG vaccination, induces a higher frequency and number of lung IL-17 producing 
CD4+ T cells. In contrast, in TLR4 -/- mice, BCG immunization, does not impact the IL-17 CD4+ T 
cell response, and both vaccinated and unvaccinated TLR4 -/- -infected mice exhibited similar 
levels of IL-17+ CD4+ T cells. As explained above, vaccination induces a population of 17-producing 
cells that facilitate the influx of memory protective effector T cells. If so, then this does not explain 
the similar BCG-induced protection in TLR4 -/- BCG-vaccinated mice compared to WT BCG-
vaccinated animals, in which the lung IL-17 CD4+ T cell response was not potentiated by 
vaccination. Thus, our results suggest that having lower levels of IL-17 production may not impact 
the BCG-induced protection. It will be interesting to investigate whether in TLR4 -/- mice in response 
to BCG, other mechanisms can compensate the lack of vaccine-induced IL-17, or alternatively if 
the increased production of IL-17 in TLR4 -/- during primary infection with 02-171 Mb infection 
was sufficient and BCG could not improve such response. Indeed, robust IL-17 responses do not 
necessarily associate with better protection, because boosting BCG vaccinated mice with MVA85A 
did not increase the protective efficacy of the BCG vaccine against Mtb, despite dramatically 
increased IL-17 and IFN- responses [146]. Additionally, repeated BCG vaccination of Mtb infected 
mice also results in increased IL-17 responses, neutrophil recruitment and consequently lung 
tissue damage [94].  
We next evaluated the lung inflammation in both strains of mice. We found that BCG vaccination 
reduced the formation of severe inflammatory foci induced by 02-171 Mtb strain in both WT and 
TLR4 -/- mice. At day 90 post-infection, unvaccinated TLR4 -/- mice appear to exhibit a reduced 
lung inflammation as compared with unvaccinated WT animals. This is in line with, BCG-induced 
IL-17 production was not associated with increased lung inflammation, being rather associated 
with immunopathology control. Thus, we hypothesized that vaccine-induced IL-17 production might 
be related with control of lung tissue damage. Indeed, we found that unvaccinated 02-171-infected 
TLR4 -/- mice showed a higher production of IL-17 compared with unvaccinated WT mice, which 
is correlated with reduced lung inflammation in TLR4 -/- unvaccinated mice compared to WT 
unvaccinated-ones. The increased IL-17 production in vaccinated WT mice also correlates with 
reduced lung inflammation. Indeed, vaccinated TLR4 -/- mice, in which IL-17 was not further 
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induced by BCG, the improvement in lung inflammation induced by BCG, does not seem so 
pronounced. Furthermore, a recent study showed that in mice IL-17 may induce disease-associated 
tissue inflammation via TLR4 signaling [147]. In this study IL-17 was overexpressed through 
adenovirus-mediated gene transfer in TLR4 -/- mice, and the authors found an absence of 
neutrophil accumulation, and lack of expression of proinflammatory cytokines downstream of TLR4 
in multiple tissues, suggesting that TLR4 may act downstream of IL-17 [147]. This is in accordance 
with our results because in TLR4 -/- unvaccinated mice, compared to WT unvaccinated-ones, 
although we had more IL-17, we observed less lung inflammation, suggesting that TLR4 triggering 
may be downstream IL-17-induced inflammation. However, these issues need further investigation. 
In a future approach, it will be important to perform a morphometric analysis to score lung 
inflammation, in a more accurate way. 
The idea that IFN- is needed but not sufficient for Mtb control is supported by several studies 
using deficient mouse models [116]. For instance, GM-CSF deficient mice succumbed quickly 
following Mtb infection [148]. As these mice produce IFN-, their failure to limit Mtb infection point 
out that other important pathways are essential for protective immunity against Mtb infection [116]. 
It has been reported that GM-CSF production could contribute to host resistance against TB [116]. 
Indeed, the presence of GM-CSF-specific autoantibodies that block GM-CSF functionality have been 
associated with pulmonary TB in healthy people [116]. Our results further support this idea, since 
both WT and TLR4 -/- vaccinated mice showed increased frequency and number of GM-CSF-
producing CD4+ T cells. Thus, other immune factors beyond IFN- and IL-17, such as GM-CSF 
needs to be considered as a possible important player in vaccination.  
Further investigation is needed in order to identify other immunological functions that protect 
against Mtb infection and to define the T cell responses that must be induced to optimize vaccine 
efficiency. Furthermore, such investigations will certainly contribute to define and validate 
biomarkers of protective immunity against Mtb infection, that gain increased importance with the 
appearance of novel TB vaccine candidates. 
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